Standard- vs High-Dose Clopidogrel Based on Platelet F Coronary Intervention

JAMA - Journal of the American Medical Association

305, 1097

DOI: 10.1001/jama.2011.290

Citation Report

#	Article	IF	Citations
1	Biomimetic actuators: where technology and cell biology merge. Cellular and Molecular Life Sciences, 2004, 61, 2497-2509.	2.4	51
2	Oral Antiplatelet Therapy in Patients with Diabetes Mellitus and Acute Coronary Syndromes. Trends in Cardiovascular Medicine, 2010, 20, 211-217.	2.3	3
3	High-dose clopidogrel, prasugrel or ticagrelor: trying to unravel a skein into a ball. Drugs and Therapy Studies, 2010, 1, 13.	0.6	0
4	The future of platelet function testing to guide therapy in clopidogrel low and enhanced responders. Expert Review of Cardiovascular Therapy, 2011, 9, 999-1014.	0.6	4
5	No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting. European Heart Journal, 2011, 32, 1605-1613.	1.0	174
6	Platelet Reactivity and Cardiovascular Outcomes After Percutaneous Coronary Intervention. Circulation, 2011, 124, 1132-1137.	1.6	381
7	Almanac 2011: stable coronary artery disease. The national society journals present selected research that has driven recent advances in clinical cardiology. Revista Portuguesa De Cardiologia, 2011, 30, 869-878.	0.2	0
8	Unraveling Myths of Platelet Function and Genetic Testing. Journal of the American College of Cardiology, 2011, 57, 2484-2486.	1.2	9
9	We Need Further Studies for the Development of â€œOptimized Antiplatelet Therapyâ€•Based on Ethnicity. Journal of the American College of Cardiology, 2011, 58, 198.	1.2	0
10	Vasovagal Syncope as a Cause of Syncope in Long-QT Syndrome. Journal of the American College of Cardiology, 2011, 58, 199-200.	1.2	0
12	Impact of Platelet Reactivity on Clinical Outcomes After Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2011, 58, 1945-1954.	1.2	383
13	2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2011, 58, e44-e122.	1.2	2,027
14	On-Clopidogrel Platelet Reactivity. Journal of the American College of Cardiology, 2011, 58, 1955-1957.	1.2	0
15	The Year in Nonâ€“ST-Segment Elevation Acute Coronary Syndrome. Journal of the American College of Cardiology, 2011, 58, 2342-2354.	1.2	7
16	A Point-of-Care Platelet Function Assay and C-Reactive Protein for Prediction of Major Cardiovascular Events After Drug-Eluting Stent Implantation. Journal of the American College of Cardiology, 2011, 58, 2630-2639.	1.2	63
17	The Role of Platelet Function Testing and Genotyping in the Stented Patient Treated With Clopidogrel. Journal of the American College of Cardiology, 2011, 58, 2701-2702.	1.2	0
18	Personalized Therapy Following Drug-Eluting Stenting Using Platelet Function Testing and C-Reactive Protein. Journal of the American College of Cardiology, 2011, 58, 2640-2641.	1.2	0
19	Platelets and endothelium: Two key players in percutaneous coronary intervention. Archives of Cardiovascular Diseases, 2011, 104, 601-603.	0.7	2

#	Article	IF	Citations
20	The effect of ticagrelor versus clopidogrel on high on-treatment platelet reactivity: Combined analysis of the ONSET/OFFSET and RESPOND studies. American Heart Journal, 2011, 162, 160-165.	1.2	75
21	Relationship between clopidogrel-induced platelet P2Y12 inhibition and stent thrombosis or myocardial infarction after percutaneous coronary interventionâ€"A case-control study. American Heart Journal, 2011, 162, 363-371.	1.2	7
22	Treatment with Adenosine Diphosphate Receptor Inhibitorsâ€"Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) study design: Expanding the paradigm of longitudinal observational research. American Heart Journal, 2011, 162, 844-851.	1.2	51
23	Platelet reactivity in patients with chronic kidney disease receiving adjunctive cilostazol compared with a high-maintenance dose of clopidogrel: Results of the Effect of Platelet Inhibition According to Clopidogrel Dose in Patients with Chronic Kidney Disease (PIANO-2 CKD) randomized study. American Heart Journal, 2011, 162, 1018-1025.	1.2	47
24	Clopidogrel up-titration versus standard dose in patients with high residual platelet reactivity after percutaneous coronary intervention: A single-center pilot randomised study. International Journal of Cardiology, 2011, 150, 231-232.	0.8	7
25	ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). European Heart Journal, 2011, 32, 2999-3054.	1.0	2,995
26	Determination of cut-off levels for on-clopidogrel platelet aggregation based on functional CYP2C19 gene variants in patients undergoing elective percutaneous coronary intervention. Thrombosis Research, 2011, 128, e130-e136.	0.8	29
27	Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450-2C19 (CYP2C19) Genotype and Clopidogrel Therapy. Clinical Pharmacology and Therapeutics, 2011, 90, 328-332.	2.3	422
29	Antiplatelet drug therapy: role of pharmacodynamic and genetic testing. Future Cardiology, 2011, 7, 381-402.	0.5	13
30	Almanac 2011: Stable coronary artery disease. The national society journals present selected research that has driven recent advances in clinical cardiology. Revista Portuguesa De Cardiologia (English) Tj ETQq1 1 0.784314 rgBT /Overloc	1.2	4
31	Prasugrel overcomes high on-clopidogrel platelet reactivity in chronic coronary artery disease patients more effectively than high dose (150 mg) clopidogrel. American Heart Journal, 2011, 162, 733-739.	1.2	60
32	Clinical, genetic and confounding factors determine the dynamics of the in vitro response/non response to clopidogrel. Thrombosis and Haemostasis, 2011, 106, 211-218.	1.8	33
33	Clopidogrel response variability and the advent of personalised antiplatelet therapy. Thrombosis and Haemostasis, 2011, 106, 265-271.	1.8	29
34	Platelet function profiles in the elderly: Results of a pharmacodynamic study in patients on clopidogrel therapy and effects of switching to prasugrel 5 mg in patients with high platelet reactivity. Thrombosis and Haemostasis, 2011, 106, 1149-1157.	1.8	29
35	Role of cytochrome P450 genotype in the steps toward personalized drug therapy. Pharmacogenomics and Personalized Medicine, 2011, 4, 123.	0.4	20
36	Multiple electrode aggregometry and vasodilator stimulated phosphoprotein-phosphorylation assay in clinical routine for prediction of postprocedural major adverse cardiovascular events. Thrombosis and Haemostasis, 2011, 106, 230-239.	1.8	41
37	Emerging Therapies for Acute Coronary Syndromes. Frontiers in Pharmacology, 2011, 2, 61.	1.6	2
38	Influence of Platelet Reactivity on Outcome of Patients With Acute Myocardial Infarction Undergoing Primary Angioplasty. Circulation Journal, 2011, 75, 2050-2051.	0.7	2

#	Article	IF	Citations
39	Cilostazol to Overcome High On-Treatment Platelet Reactivity in Korean Patients Treated With Clopidogrel and Calcium-Channel Blocker. Circulation Journal, 2011, 75, 2534-2536.	0.7	5
40	Antiâ€platelet therapy: ADP receptor antagonists. British Journal of Clinical Pharmacology, 2011, 72, 647-657.	1.1	87
41	Antiplatelet effects of prasugrel vs. double clopidogrel in patients on hemodialysis and with high onâ€treatment platelet reactivity. Journal of Thrombosis and Haemostasis, 2011, 9, 2379-2385.	1.9	72
42	Pharmacogenetics: past, present and future. Drug Discovery Today, 2011, 16, 852-861.	3.2	80
43	Safety and Efficacy of Clopidogrel Reloading in Patients on Chronic Clopidogrel Therapy Who Present With an Acute Coronary Syndrome and Undergo Percutaneous Coronary Intervention. American Journal of Cardiology, 2011, 107, 1779-1782.	0.7	8
44	Usefulness of High Clopidogrel Maintenance Dose According to CYP2C19 Genotypes in Clopidogrel Low Responders Undergoing Coronary Stenting for Non ST Elevation Acute Coronary Syndrome. American Journal of Cardiology, 2011, 108, 760-765.	0.7	40
45	Comparison of Platelet Reactivity and Clopidogrel Response in Patients â‰¥75 Years Versus >75 Years Undergoing Percutaneous Coronary Intervention for Nonâ€“ST-Segment Elevation Acute Coronary Syndrome. American Journal of Cardiology, 2011, 108, 1411-1416.	0.7	18
46	2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention. Catheterization and Cardiovascular Interventions, 2013, 82, E266-355.	0.7	97
47	The pharmacogenetics of antiplatelet agents: towards personalized therapy?. Nature Reviews Cardiology, 2011, 8, 560-571.	6.1	38
48	Personalized vascular medicine: Individualizing drug therapy. Vascular Medicine, 2011, 16, 391-404.	0.8	16
49	Can resistance to aspirin be reversed after an additional dose?. Journal of Thrombosis and Thrombolysis, 2011, 32, 356-361.	1.0	13
50	The P2Y12 receptor as a target of antithrombotic drugs. Purinergic Signalling, 2011, 7, 325-332.	1.1	14
51	Prasugrel vs. Ticagrelor in acute coronary syndromes: Which one to choose?. Wiener Klinische Wochenschrift, 2011, 123, 468-476.	1.0	5
52	Optimizing of thienopyridine therapy by multiple electrode platelet aggregometry in clopidogrel low responders undergoing PCI. Clinical Research in Cardiology, 2011, 100, 907-914.	1.5	7
53	Personalized Medicine and Cardiovascular Disease: From Genome to Bedside. Current Cardiovascular Risk Reports, 2011, 5, 542-551.	0.8	1
55	Personalized Antiplatelet Therapy: Review of the Latest Clinical Evidence. Current Cardiology Reports, 2011, 13, 296-302.	1.3	15
56	Beyond Aspirin and Clopidogrel: Is There a Need for Additional Antiplatelet Therapy in ACS?. Current Cardiology Reports, 2011, 13, 303-311.	1.3	1
57	Genotypic and Phenotypic Assessment of Platelet Function and Response to P2Y12 Antagonists. Current Cardiology Reports, 2011, 13, 439-450.	1.3	2

#	Article	IF	Citations
58	Laboratory evaluation of clopidogrel responsiveness by platelet function and genetic methods. American Journal of Hematology, 2011, 86, 1032-1034.	2.0	23
59	Platelet Inhibition by Adjunctive Cilostazol Versus High Maintenance-Dose Clopidogrel in Patients With Acute Myocardial Infarction According to Cytochrome P450 2C19 Genotype. JACC: Cardiovascular Interventions, 2011, 4, 381-391.	1.1	46
60	Optimizing Platelet Inhibition in Clopidogrel Poor Metabolizers. JACC: Cardiovascular Interventions, 2011, 4, 411-414.	1.1	22
61	Antiplatelet options for secondary prevention in acute coronary syndromes. Expert Review of Cardiovascular Therapy, 2011, 9, 1403-1415.	0.6	1
62	The GRAVITAS of clopidogrel dose. Nature Reviews Cardiology, 2011, 8, 305-305.	6.1	0
63	Prescribing proton pump inhibitor and clopidogrel together. Current Opinion in Gastroenterology, 2011, 27, 558-564.	1.0	14
64	Almanac 2011: stable coronary artery disease. An editorial overview of selected research that has driven recent advances in clinical cardiology. Heart, 2011, 97, 1552-1559.	1.2	7
65	Recent developments in the use of antiplatelet agents to prevent cardiovascular events. Future Cardiology, 2011, 7, 403-413.	0.5	6
66	Standard- vs High-Dose Clopidogrel After Percutaneous Coronary Intervention. JAMA - Journal of the American Medical Association, 2011, 305, 2520.	3.8	2
67	High Residual Platelet Reactivity and Thrombotic Events. JAMA - Journal of the American Medical Association, 2011, 306, 2561-2561.	3.8	1
68	Dosing Clopidogrel Based on CYP2C19 Genotype and the Effect on Platelet Reactivity in Patients With Stable Cardiovascular Disease. JAMA - Journal of the American Medical Association, 2011, 306, 2221-8.	3.8	313
69	Applying Platelet Function Testing in Clinical Practice. JAMA - Journal of the American Medical Association, 2011, 306, 1260.	3.8	9
70	An Initial Experiment With Personalized Antiplatelet Therapy. JAMA - Journal of the American Medical Association, 2011, 305, 1136.	3.8	36
71	High Residual Platelet Reactivity and Thrombotic Events--Reply. JAMA - Journal of the American Medical Association, 2011, 306, 2561-2562.	3.8	0
72	Effect of CYP2C19*2 and *3 Loss-of-Function Alleles on Platelet Reactivity and Adverse Clinical Events in East Asian Acute Myocardial Infarction Survivors Treated With Clopidogrel and Aspirin. Circulation: Cardiovascular Interventions, 2011, 4, 585-594.	1.4	112
73	A Clopidogrel-Insensitive Inducible Pool of P2Y₁₂ Receptors Contributes to Thrombus Formation: Inhibition by Elinogrel, a Direct-Acting, Reversible P2Y₁₂ Antagonist. Journal of Pharmacology and Experimental Therapeutics, 2011, 339, 54-61.	1.3	28
74	Responsiveness to P2Y12 receptor inhibitors. Current Opinion in Cardiology, 2011, 26, S31-S37.	0.8	10
75	Standard- vs High-Dose Clopidogrel After Percutaneous Coronary Intervention. JAMA - Journal of the American Medical Association, 2011, 305, 2520.	3.8	1

#	Article	IF	Citations
76	High Residual Platelet Reactivity After Clopidogrel Loading and Long-term Cardiovascular Events Among Patients With Acute Coronary Syndromes Undergoing PCI. JAMA - Journal of the American Medical Association, 2011, 306, 1215.	3.8	361
77	Platelet-Mediated Thrombosis and Drug-Eluting Stents. Circulation: Cardiovascular Interventions, 2011, 4, 629-637.	1.4	7
78	The Clinical Relevance of Response Variability to Antiplatelet Therapy. Hematology American Society of Hematology Education Program, 2011, 2011, 70-75.	0.9	17
79	Large interventricular septal aneurysm with thrombo-embolism in a healthy woman. European Heart Journal, 2011, 32, 1613-1613.	1.0	3
80	Phenotyping Patient-Derived Cells for Translational Studies in Cardiovascular Disease. Circulation, 2011, 124, 2444-2455.	1.6	5
81	Clopidogrel: To Test or Not to Test? That Is the Questionâ€"Still. Clinical Chemistry, 2011, 57, 659-661.	1.5	6
82	Response to Letters Regarding Article, â€œAspirin Plus Clopidogrel Versus Aspirin Alone After Coronary Artery Bypass Grafting: The Clopidogrel After Surgery for Coronary Artery Disease (CASCADE) Trialâ€• Circulation, 2011, 124, .	1.6	1
83	Current Evidence for Genetic Testing in Clopidogrel-Treated Patients Undergoing Coronary Stenting. Circulation: Cardiovascular Interventions, 2011, 4, 505-513.	1.4	16
84	How to Minimize Stent Thrombosis. Circulation, 2011, 124, 1283-1287.	1.6	67
85	Assessment of oral antithrombotic therapy by platelet function testing. Nature Reviews Cardiology, 2011, 8, 572-579.	6.1	21
86	Pharmacogenetics of antiplatelet therapy: ready for clinical application?. Heart, 2011, 97, 1268-1276.	1.2	7
87	Update on selecting and adjusting antiplatelet therapy for prevention of noncardiogenic, recurrent ischemic stroke. Expert Review of Cardiovascular Therapy, 2011, 9, 1295-1303.	0.6	0
88	2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. Circulation, 2011, 124, e574-651.	1.6	1,946
89	Platelet Function in Patients with Diabetes Mellitus: From a Theoretical to a Practical Perspective. International Journal of Endocrinology, 2011, 2011, 1-14.	0.6	126
90	CYP2C19 Genetic Testing Should Not Be Done in All Patients Treated With Clopidogrel Who Are Undergoing Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2011, 4, 514-521.	1.4	19
92	Recent Publications on Medications and Pharmacy. Hospital Pharmacy, 2011, 46, 458-460.	0.4	0
93	No Association of ABCB1 C3435T Genotype With Clopidogrel Response or Risk of Stent Thrombosis in Patients Undergoing Coronary Stenting. Circulation: Cardiovascular Interventions, 2012, 5, 82-88.	1.4	37
94	Enhanced clopidogrel response in smokers is reversed after discontinuation as assessed by VerifyNow assay: additional evidence for the concept of â€˜smokersâ€™ paradox'. Heart, 2012, 98, 1000-1006.	1.2	37

#	Article	IF	Citations
95	Increased Atherothrombotic Burden in Patients with Diabetes Mellitus and Acute Coronary Syndrome: A Review of Antiplatelet Therapy. Cardiology Research and Practice, 2012, 2012, 1-18.	0.5	26
96	Advances in the monitoring of anti-P2Y12therapy. Platelets, 2012, 23, 510-525.	1.1	22
97	Periprocedural antithrombotic strategies in acute ischemic stroke interventional therapy. Neurology, 2012, 79, S174-81.	1.5	17
98	Clopidogrel and Genetic Testing. Cardiology in Review, 2012, 20, 96-100.	0.6	11
99	Updating an Institutional Chest Pain Algorithm. Critical Pathways in Cardiology, 2012, 11, 107-113.	0.2	6
100	The Role of Platelet Reactivity and Genotype Testing in the Prevention of Atherothrombotic Cardiovascular Events Remains Unproven. Circulation, 2012, 125, 1288-1303.	1.6	51
101	Treatment algorithm in patients with NSTEMI and unstable angina. , 2012, , 331-346.		0
102	Letter by Nezami et al Regarding Article, â€œPlatelet Reactivity and Cardiovascular Outcomes After Percutaneous Coronary Intervention: A Time-Dependent Analysis of the Gauging Responsiveness With a VerifyNow P2Y12 Assay: Impact on Thrombosis and Safety (GRAVITAS) Trialâ€• Circulation, 2012, 125, e569; author reply e571-2.	1.6	0
103	Clopidogrel and CYP2C19 Testing: Ready for Clinical Prime Time?. Clinical Chemistry, 2012, 58, 154-157.	1.5	7
104	The 2012 ACCF/AHA Focused Update of the Unstable Angina/Non-ST-Elevation Myocardial Infarction (UA/NSTEMI) Guideline: A Critical Appraisal. Methodist DeBakey Cardiovascular Journal, 2021, 8, 26.	0.5	17
105	Measured Drug Effect and Cardiovascular Outcomes in Patients Receiving Platelet P2Y‹sub›12‹/sub›Receptor Antagonists. JAMA - Journal of the American Medical Association, 2012, 308, 1806.	3.8	7
106	Walking the tightrope between efficacy and bleeding. Nature Reviews Cardiology, 2012, 9, 69-71.	6.1	5
107	Secondary stroke preventionâ€”personalized antiplatelet therapy. Nature Reviews Neurology, 2012, 8, 536-537.	4.9	3
108	Advances in platelet function testing assessing bleeding complications in patients with coronary artery disease. Platelets, 2012, 23, 537-551.	1.1	17
109	Prevalence of poor biological response to clopidogrel. Thrombosis and Haemostasis, 2012, 107, 494-506.	1.8	81
110	Latest Evidence in Personalized Antiplatelet Therapy in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. Hospital Practice (1995), 2012, 40, 104-117.	0.5	1
111	Delayed Ipsilateral Parenchymal Hemorrhage Following Flow Diversion for the Treatment of Anterior Circulation Aneurysms. American Journal of Neuroradiology, 2012, 33, 603-608.	1.2	166
112	Long-term antiplatelet therapy. Current Opinion in Cardiology, 2012, 27, 347-354.	0.8	1

#	Article	IF	Citations
113	Platelet Function Testing and Genotyping Improve Outcome in Patients Treated With Antithrombotic Agents. Circulation, 2012, 125, 1276-1287.	1.6	111
114	High on-thienopyridine platelet reactivity in elderly coronary patients: the SENIOR-PLATELET study. European Heart Journal, 2012, 33, 1241-1249.	1.0	127
115	Toward a therapeutic window for antiplatelet therapy in the elderly. European Heart Journal, 2012, 33, 1187-1189.	1.0	18
116	Personalized antiplatelet therapy: state of the art. JRSM Cardiovascular Disease, 2012, 1, 1-10.	0.4	1
117	Platelet Function Testing in Atherothrombotic Disease. Current Pharmaceutical Design, 2012, 18, 5379-5391.	0.9	35
118	Interindividual Variability in the Efficacy of Oral Antiplatelet Drugs: Definitions, Mechanisms and Clinical Importance. Current Pharmaceutical Design, 2012, 18, 5344-5361.	0.9	59
119	Pharmacogenetics of Clopidogrel. Current Pharmaceutical Design, 2012, 18, 5309-5327.	0.9	16
120	Standard- vs High-Dose Clopidogrel Based on Platelet Function Testing After Percutaneous Coronary Intervention: The GRAVITAS Randomized Trial. Yearbook of Critical Care Medicine, 2012, 2012, 36-39.	0.2	0
121	Invasive management of the acute coronary syndromes. Interventional Cardiology, 2012, 4, 279-285.	0.0	0
122	Options to Overcome Clopidogrel Response Variability. Circulation Journal, 2012, 76, 287-292.	0.7	27
123	Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial. Lancet, The, 2012, 379, 1705-1711.	6.3	341
124	Personalised antiplatelet treatment: a RAPIDly moving target. Lancet, The, 2012, 379, 1680-1682.	6.3	8
125	Platelet Function During Extended Prasugrel and Clopidogrel Therapy for Patients With ACS Treated Without Revascularization. JAMA - Journal of the American Medical Association, 2012, 308, 1785.	3.8	200
126	Antiplatelets in acute coronary syndrome: personal perspectives. Expert Review of Cardiovascular Therapy, 2012, 10, 1487-1496.	0.6	8
127	Thienopyridines and Other ADP-Receptor Antagonists. Handbook of Experimental Pharmacology, 2012, , 165-198.	0.9	24
128	Translational platelet research in patients with coronary artery disease: What are the major knowledge gaps?. Thrombosis and Haemostasis, 2012, 108, 12-20.	1.8	9
129	Clinical Pharmacogenomics of Warfarin and Clopidogrel. Journal of Pharmacy Practice, 2012, 25, 428-438.	0.5	13
130	Genetic and non-genetic factors affecting the response to clopidogrel therapy. Expert Opinion on Pharmacotherapy, 2012, 13, 663-683.	0.9	38

#	Article	IF	Citations
131	Personalizing Antiplatelet Therapy With Clopidogrel. Clinical Pharmacology and Therapeutics, 2012, 92, 476-85.	2.3	12
132	Genetic Polymorphisms Affecting Drug Metabolism. Advances in Pharmacology, 2012, 63, 137-167.	1.2	35
133	Republished article: Pharmacogenetics of antiplatelet therapy: ready for clinical application?. Postgraduate Medical Journal, 2012, 88, 176-184.	0.9	0
134	Almanac 2012: interventional cardiology: The national society journals present selected research that has driven recent advances in clinical cardiology. Heart, 2012, 98, 1701-1709.	1.2	13
135	Biomarkers in acute coronary artery disease. Wiener Medizinische Wochenschrift, 2012, 162, 489-498.	0.5	9
136	Prasugrel Versus High Dose Clopidogrel to Overcome Early High on Clopidogrel Platelet Reactivity in Patients with ST Elevation Myocardial Infarction. Cardiovascular Drugs and Therapy, 2012, 26, 393-400.	1.3	37
137	Value of CYP2C19 *2 and *17 Genotyping in Clinical Practice. Promising but Not Ready Yet. Revista Espanola De Cardiologia (English Ed), 2012, 65, 205-207.	0.4	2
138	ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation. Revista Espanola De Cardiologia (English Ed), 2012, 65, 173.	0.4	183
139	Platelet aggregation at discharge: A useful tool in acute coronary syndromes?. Revista Portuguesa De Cardiologia (English Edition), 2012, 31, 545-554.	0.2	5
140	Endovascular treatment of symptomatic intracranial atheromatous stenosis: A single center study of 21 consecutive cases. Journal of Neuroradiology, 2012, 39, 332-341.	0.6	2
141	Platelet aggregation at discharge: A useful tool in acute coronary syndromes?. Revista Portuguesa De Cardiologia, 2012, 31, 545-554.	0.2	5
142	Antiplatelet therapy in acute coronary syndromes. Expert Opinion on Pharmacotherapy, 2012, 13, 27-42.	0.9	4
143	Valor de la determinaciÃ³n del genotipo de CYP2C19 *2 y *17 en la prÃ¡ctica clÃnica. Prometedor, aunque todavÃa no estÃ¡ listo. Revista Espanola De Cardiologia, 2012, 65, 205-207.	0.6	7
145	GuÃa de prÃ¡ctica clÃnica de la ESC para el manejo del sÃndrome coronario agudo en pacientes sin elevaciÃ³n persistente del segmento ST. Revista Espanola De Cardiologia, 2012, 65, 173.e1-173.e55.	0.6	31
146	Platelet aggregation is dependent on platelet count in patients with coronary artery disease. Thrombosis Research, 2012, 129, 56-61.	0.8	100
147	Antiplatelet therapy: Controversial aspects. Thrombosis Research, 2012, 129, 225-229.	0.8	17
148	Operational Implementation of Prospective Genotyping for Personalized Medicine: The Design of the Vanderbilt PREDICT Project. Clinical Pharmacology and Therapeutics, 2012, 92, 87-95.	2.3	370
150	Usefulness of the VerifyNow P2Y12 assay to evaluate the antiplatelet effects of ticagrelor and clopidogrel therapies. American Heart Journal, 2012, 164, 35-42.	1.2	77

#	Article	IF	Citations
151	High on Treatment Platelet Reactivity. Heart Lung and Circulation, 2012, 21, 12-21.	0.2	19
152	Newer Pharmaceutical Agents for STEMI Interventions. Interventional Cardiology Clinics, 2012, 1, 429-440.	0.2	0
153	Clopidogrel in Coronary Artery Disease: Update 2012. Advances in Cardiology, 2012, 47, 31-38.	2.6	4
154	Periprocedural variations of platelet reactivity during elective percutaneous coronary intervention. Journal of Thrombosis and Haemostasis, 2012, 10, 2452-2461.	1.9	34
155	Effects of Proton Pump Inhibitors on Platelet Function in Patients Receiving Clopidogrel. Drug Safety, 2012, 35, 127-139.	1.4	26
156	The Evolution of Antiplatelet Therapy in the Treatment of Acute Coronary Syndromes. Drugs, 2012, 72, 2087-2116.	4.9	106
157	New Directions in Antiplatelet Therapy. Circulation: Cardiovascular Interventions, 2012, 5, 433-445.	1.4	61
158	Inconsistencies surrounding the risk of adverse outcomes with concomitant use of clopidogrel and proton pump inhibitors. Expert Opinion on Drug Safety, 2012, 11, 275-284.	1.0	2
159	Platelet Function in Health and Disease: from Molecular Mechanisms, Redox Considerations to Novel Therapeutic Opportunities. Antioxidants and Redox Signaling, 2012, 17, 1447-1485.	2.5	57
160	Acute coronary syndromes: considerations for improved acceptance and implementation of management guidelines. Expert Review of Cardiovascular Therapy, 2012, 10, 489-503.	0.6	11
161	Stent thrombosis in patients with chronic kidney disease. Expert Review of Cardiovascular Therapy, 2012, 10, 617-626.	0.6	0
162	Stent thrombosis: an overview. Expert Review of Cardiovascular Therapy, 2012, 10, 599-615.	0.6	16
163	Comparison between initial and chronic response to clopidogrel therapy after coronary stenting for acute coronary syndrome and influence on clinical outcomes. American Heart Journal, 2012, 164, 327-333.	1.2	8
164	Clopidogrel resistance â€“ A clear problem with an unclear solution. Indian Heart Journal, 2012, 64, 353-355.	0.2	4
165	CYP2C19*2/ABCB1-C3435T polymorphism and risk of cardiovascular events in coronary artery disease patients on clopidogrel: Is clinical testing helpful?. Indian Heart Journal, 2012, 64, 341-352.	0.2	24
166	Platelet Biology and Response to Antiplatelet Therapy in Women. Journal of the American College of Cardiology, 2012, 59, 891-900.	1.2	65
167	Influence of Genetic Polymorphisms on the Effect of High- and Standard-Dose Clopidogrel After Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2012, 59, 1928-1937.	1.2	127
168	The Year in Interventional Cardiology. Journal of the American College of Cardiology, 2012, 59, 1497-1508.	1.2	6

#	Article	IF	Citations
169	Clinical Application of Cardiovascular Pharmacogenetics. Journal of the American College of Cardiology, 2012, 60, 9-20.	1.2	65
170	A Randomized Trial of Prasugrel Versus Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After Elective Percutaneous Coronary Intervention With Implantation of Drug-Eluting Stents. Journal of the American College of Cardiology, 2012, 59, 2159-2164.	1.2	569
171	Prognostic Value of a High On-Clopidogrel Treatment Platelet Reactivity in Bivalirudin Versus Abciximab Treated Nonâ€“ST-Segment Elevation Myocardial Infarction Patients. Journal of the American College of Cardiology, 2012, 60, 369-377.	1.2	40
172	Platelet Reactivity and Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2012, 60, 378-380.	1.2	0
173	The Year in Atherothrombosis. Journal of the American College of Cardiology, 2012, 60, 932-942.	1.2	14
175	Cigarette Smoking Is Associated With a Dose-Response Effect in Clopidogrel-Treated Patients With Diabetes Mellitus and Coronary Artery Disease. JACC: Cardiovascular Interventions, 2012, 5, 293-300.	1.1	48
176	Different Prognostic Significance of High On-Treatment Platelet Reactivity as Assessed by the VerifyNow P2Y12 Assay After Coronary Stenting in Patients With and Without Acute Myocardial Infarction. JACC: Cardiovascular Interventions, 2012, 5, 259-267.	1.1	66
177	A Therapeutic Window for Platelet Reactivity for Patients Undergoing Elective Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2012, 5, 281-289.	1.1	82
178	High Platelet Reactivity on Clopidogrel Therapy Correlates With Increased Coronary Atherosclerosis and Calcification. JACC: Cardiovascular Imaging, 2012, 5, 540-549.	2.3	48
179	Effect of Tailored Antiplatelet Therapy on Periprocedural Myonecrosis in Patients With Diabetes Mellitus (from the DM-Verify Now Trial). American Journal of Cardiology, 2012, 110, 1749-1755.	0.7	5
180	Evolving strategies in the management of acute coronary syndromes with oral antiplatelet agents. Cor Et Vasa, 2012, 54, e32-e38.	0.1	3
181	Resistance to antiplatelet treatment: The clinical relevance of platelet function assays. Cor Et Vasa, 2012, 54, e305-e313.	0.1	3
182	Platelet aggregometry in the presence of PGE1 provides a reliable method for cilostazol monitoring. Thrombosis Research, 2012, 130, 616-621.	0.8	9
183	Antithrombotics for secondary prevention of noncardioembolic ischaemic stroke. Nature Reviews Neurology, 2012, 8, 223-235.	4.9	16
184	Bedside Monitoring to Adjust Antiplatelet Therapy for Coronary Stenting. New England Journal of Medicine, 2012, 367, 2100-2109.	13.9	788
185	Biomarkers in Cardiovascular Clinical Trials: Past, Present, Future. Clinical Chemistry, 2012, 58, 45-53.	1.5	35
186	Pharmacodynamic properties of antiplatelet agents: current knowledge and future perspectives. Expert Review of Clinical Pharmacology, 2012, 5, 319-336.	1.3	44
187	Platelet function monitoring in patients on clopidogrel: What should we learn from GRAVITAS?. Platelets, 2012, 23, 167-176.	1.1	6

#	Article	IF	Citations
189	InforMatrix: ADP antagonists in acute coronary syndromes. Expert Opinion on Pharmacotherapy, 2012, 13, 357-385.	0.9	0
190	Impact of Platelet Function Test on Platelet Responsiveness and Clinical Outcome After Coronary Stent Implantation: Platelet Responsiveness and Clinical Outcome. Korean Circulation Journal, 2012, 42, 382.	0.7	11
191	Stent Thrombosis: Incidence, Predictors and New Technologies. Thrombosis, 2012, 2012, 1-12.	1.4	53
192	Towards Personalized Medicine Based on Platelet Function Testing for Stent Thrombosis Patients. Thrombosis, 2012, 2012, 1-11.	1.4	9
193	Effects of pioglitazone on platelet P2Y12-mediated signalling in clopidogrel-treated patients with type 2 diabetes mellitus. Thrombosis and Haemostasis, 2012, 108, 930-936.	1.8	13
194	Effects of 600 mg versus 300 mg Loading Dose of Clopidogrel in Asian Patients with ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Long-Term Follow-Up Study. Yonsei Medical Journal, 2012, 53, 906.	0.9	3
195	Antiplatelet Drugs. Chest, 2012, 141, e89S-e119S.	0.4	318
196	Platelet Function Testing in Patients With Coronary Artery Disease. Circulation, 2012, 125, 3073-3075.	1.6	10
197	Network meta-analysis of prasugrel, ticagrelor, high- and standard-dose clopidogrel in patients scheduled for percutaneous coronary interventions. Thrombosis and Haemostasis, 2012, 108, 318-327.	1.8	35
198	Aspirin Resistance: Current Status and Role of Tailored Therapy. Clinical Cardiology, 2012, 35, 673-680.	0.7	51
200	High leukocyte count and interleukin-10 predict high on-treatment-platelet-reactivity in patients treated with clopidogrel. Journal of Thrombosis and Thrombolysis, 2012, 33, 349-354.	1.0	17
201	Tailoring clopidogrel dose according to multiple electrode aggregometry decreases the rate of ischemic complications after percutaneous coronary intervention. Journal of Thrombosis and Thrombolysis, 2012, 34, 85-90.	1.0	60
202	Highlights from the IV International Symposium of Thrombosis and Anticoagulation (ISTA), October 20â€“21, 2011, Salvador, Bahia, Brazil. Journal of Thrombosis and Thrombolysis, 2012, 34, 143-163.	1.0	0
203	Platelet Function and Inhibition in Ischemic Heart Disease. Current Cardiology Reports, 2012, 14, 457-467.	1.3	15
204	Late Stent Thrombosis: The Last Remaining Obstacle in Coronary Interventional Therapy. Current Cardiology Reports, 2012, 14, 408-417.	1.3	15
206	Antiplatelet function variability in clopidogrelâ€treated patients: need for new antiplatelet agents. Fundamental and Clinical Pharmacology, 2012, 26, 2-10.	1.0	7
207	Antiâ€platelet therapy and managing ulcer risk. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 195-199.	1.4	12
208	Impact of Anemia on Platelet Response to Clopidogrel in Patients Undergoing Percutaneous Coronary Stenting. American Journal of Cardiology, 2012, 109, 1148-1153.	0.7	29

#	Article	IF	Citations
209	Almanac 2011: Stable coronary artery disease. The national society journals present selected research that has driven recent advances in clinical cardiology. Egyptian Heart Journal, 2012, 64, 59-68.	0.4	1
210	Management of acute coronary syndrome: achievements and goals still to pursue. Novel developments in diagnosis and treatment. Journal of Internal Medicine, 2012, 271, 521-536.	2.7	18
211	Response variability to clopidogrel: is tailored treatment, based on laboratory testing, the right solution?. Journal of Thrombosis and Haemostasis, 2012, 10, 327-336.	1.9	54
212	High onâ€treatment platelet reactivity assessed by various platelet function tests: is the consensusâ€defined cutâ€off of VASPâ€P platelet reactivity index too low?. Journal of Thrombosis and Haemostasis, 2012, 10, 487-489.	1.9	28
213	Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUSâ€PCI study. Journal of Thrombosis and Haemostasis, 2012, 10, 529-542.	1.9	81
214	Interaction analysis between genetic polymorphisms and pharmacodynamic effect in patients treated with adjunctive cilostazol to dual antiplatelet therapy: results of the ACCELâ€TRIPLE (Accelerated) Tj ETQq1 1 0.784314 rgBT /Overlock Journal of Clinical Pharmacology, 2012, 73, 629-640.	1.1	13
215	Justification of 150â€ƒmg clopidogrel in patients with high onâ€clopidogrel platelet reactivity. European Journal of Clinical Investigation, 2012, 42, 384-392.	1.7	37
216	Novel Antiplatelet Therapies. Current Atherosclerosis Reports, 2012, 14, 78-84.	2.0	7
217	Stent Thrombosis: Understanding and Managing a Critical Problem. Current Treatment Options in Cardiovascular Medicine, 2012, 14, 91-107.	0.4	8
218	Optimal Management of Antiplatelet Therapy and Proton Pump Inhibition Following Percutaneous Coronary Intervention. Current Treatment Options in Cardiovascular Medicine, 2012, 14, 24-38.	0.4	10
219	Aspirin and Other Antiplatelet Agents and Their Effects on Cardiovascular Disease in Type 2 Diabetes. Current Cardiovascular Risk Reports, 2012, 6, 62-70.	0.8	0
220	Role of Antiplatelet Therapy in Secondary Prevention of Acute Coronary Syndrome. Journal of Cardiovascular Translational Research, 2012, 5, 41-51.	1.1	4
221	P2Y12 platelet inhibition in clinical practice. Journal of Thrombosis and Thrombolysis, 2012, 33, 143-153.	1.0	97
222	Pharmacodynamic effects of adjunctive cilostazol therapy in patients with coronary artery disease on dual antiplatelet therapy: Impact of high onâ€treatment platelet reactivity and diabetes mellitus status. Catheterization and Cardiovascular Interventions, 2013, 81, 42-49.	0.7	18
223	CYP2C19 genotypes and their impact on clopidogrel responsiveness in percutaneous coronary intervention. International Journal of Clinical Pharmacy, 2013, 35, 621-628.	1.0	19
224	Bringing pharmacogenetics to the bedside. European Journal of Clinical Pharmacology, 2013, 69, 1189-1190.	0.8	0
225	Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update. Clinical Pharmacology and Therapeutics, 2013, 94, 317-323.	2.3	795
226	Medical Management After Coronary Stent Implantation. JAMA - Journal of the American Medical Association, 2013, 310, 189.	3.8	84

#	Article	IF	Citations
227	A Brief History of Ideas About Platelets in Health and Disease. , 2013, , xix-xliv.		6
228	ADP-Receptor Inhibitors in the Perioperative Period: The Good, the Bad, and the Ugly. Journal of Cardiothoracic and Vascular Anesthesia, 2013, 27, 779-795.	0.6	12
229	Rationale and Design of the Onâ€Treatment PLAtelet Reactivityâ€Guided Therapy Modification FOR STâ€Segment Elevation Myocardial Infarction (PLATFORM) Randomized Trial. Journal of Interventional Cardiology, 2013, 26, 221-227.	0.5	3
230	Clinical Implications of Plateletâ€"Vessel Interaction. Journal of Cardiovascular Translational Research, 2013, 6, 310-315.	1.1	16
231	Platelet Function Testing and Tailored Antiplatelet Therapy. Journal of Cardiovascular Translational Research, 2013, 6, 316-328.	1.1	34
232	Platelet Function Profiles in Patients with Diabetes Mellitus. Journal of Cardiovascular Translational Research, 2013, 6, 329-345.	1.1	46
233	Influence of Platelet Reactivity on Clinical Outcome of Patients with Stable Coronary Artery Disease. Journal of Cardiovascular Translational Research, 2013, 6, 346-354.	1.1	3
234	CYP-Mediated Pharmacologic Interference with Optimal Platelet Inhibition. Journal of Cardiovascular Translational Research, 2013, 6, 404-410.	1.1	6
235	Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet, The, 2013, 382, 1714-1722.	6.3	537
236	Below-the-knee Interventions. CardioVascular and Interventional Radiology, 2013, 36, 302-311.	0.9	41
237	Lack of association between clopidogrel responsiveness tested using point-of-care assay and prognosis of patients with coronary artery disease. Journal of Thrombosis and Thrombolysis, 2013, 36, 1-6.	1.0	5
238	The future of inpatient anticoagulation management. Journal of Thrombosis and Thrombolysis, 2013, 35, 375-386.	1.0	0
239	Platelet reactivity tests for assessing antiplatelet drug response: what the clinician needs to know. Expert Review of Cardiovascular Therapy, 2013, 11, 975-984.	0.6	4
240	Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet, The, 2013, 382, 614-623.	6.3	740
241	Bleeding and Thrombosis Risk Matters. JACC: Cardiovascular Interventions, 2013, 6, 864-866.	1.1	1
242	Clinical Implications of Very Low On-Treatment Platelet Reactivity in Patients Treated With Thienopyridine. JACC: Cardiovascular Interventions, 2013, 6, 854-863.	1.1	67
243	Triple antiplatelet therapy with addition of cilostazol to aspirin and clopidogrel for Y-stent-assisted coil embolization of cerebral aneurysms. Acta Neurochirurgica, 2013, 155, 1549-1557.	0.9	23
244	The Role of Platelet Function Testing in Risk Stratification and Clinical Decision-Making. Interventional Cardiology Clinics, 2013, 2, 607-614.	0.2	1

#	Article	IF	Citations
245	Antiplatelet Therapy and Cardiac Surgery: Review of Recent Evidence and Clinical Implications. Canadian Journal of Cardiology, 2013, 29, 1042-1047.	0.8	19
246	Prise en charge des syndromes coronariens aigus. Canadian Journal of Diabetes, 2013, 37, S494-S498.	0.4	0
247	Platelet reactivity in diabetic patients undergoing coronary stenting for acute coronary syndrome treated with clopidogrel loading dose followed by prasugrel maintenance therapy. International Journal of Cardiology, 2013, 168, 523-528.	0.8	21
248	Dual platelet inhibition in ACS - The Styrian consensus. Cor Et Vasa, 2013, 55, e131-e134.	0.1	0
249	Personalized antiplatelet treatment after percutaneous coronary intervention: The MADONNA study. International Journal of Cardiology, 2013, 167, 2018-2023.	0.8	101
250	Cost-Effectiveness of Universal and Platelet Reactivity Assay-Driven Antiplatelet Therapy in Acute Coronary Syndrome. American Journal of Cardiology, 2013, 112, 355-362.	0.7	23
251	Platelet Inhibitory Effect of Clopidogrel in Patients Treated With Omeprazole, Pantoprazole, and Famotidine: A Prospective, Randomized, Crossover Study. Clinical Cardiology, 2013, 36, 342-346.	0.7	31
252	Pharmacogenetics of antiplatelets and anticoagulants: a report on clopidogrel, warfarin and dabigatran. Pharmacogenomics, 2013, 14, 1565-1572.	0.6	19
253	Platelet Function Tests in Clinical Cardiology. Journal of the American College of Cardiology, 2013, 61, 2115-2129.	1.2	74
254	Higher body weight patients on clopidogrel maintenance therapy have lower active metabolite concentrations, lower levels of platelet inhibition, and higher rates of poor responders than low body weight patients. Journal of Thrombosis and Thrombolysis, 2014, 38, 127-36.	1.0	16
255	High post-clopidogrel platelet reactivity assessed by a point-of-care assay predicts long-term clinical outcomes in patients with ST-segment elevation myocardial infarction who underwent primary coronary stenting. International Journal of Cardiology, 2013, 167, 1877-1881.	0.8	28
256	Personalized antiplatelet therapy: The wrong approach?. Archives of Cardiovascular Diseases, 2013, 106, 481-486.	0.7	3
257	Optimal treatment of ACS patients: Issues and considerations for upstream antiplatelet therapy. International Journal of Cardiology, 2013, 163, 19-25.	0.8	3
258	Antiplatelet Drug Resistance and Variability in Response: The Role of Antiplatelet Therapy Monitoring. , 2013, , 45-112.		6
259	With so Much Attention Paid to Adenosine Diphosphate Receptor Blockers, Is There Still a Role for Aspirin Resistance?. Revista Espanola De Cardiologia (English Ed), 2013, 66, 311-312.	0.4	0
260	Dual non-responsiveness to antiplatelet treatment is a stronger predictor of cardiac adverse events than isolated non-responsiveness to clopidogrel or aspirin. International Journal of Cardiology, 2013, 167, 430-435.	0.8	35
261	Concomitant use of clopidogrel and proton pump inhibitors: impact on platelet function and clinical outcome- a systematic review. Heart, 2013, 99, 520-527.	1.2	77
262	Consensus and Update on the Definition of On-Treatment Platelet Reactivity to Adenosine Diphosphate Associated With Ischemia and Bleeding. Journal of the American College of Cardiology, 2013, 62, 2261-2273.	1.2	807

#	Article	IF	Citations
263	Management of Antiplatelet Therapy in Patients With Coronary Artery Disease Requiring Cardiac and Noncardiac Surgery. Circulation, 2013, 128, 2785-2798.	1.6	91
264	Response Variability to P2Y12 Receptor Inhibitors. JACC: Cardiovascular Interventions, 2013, 6, 1111-1128.	1.1	128
265	Current evidence for monitoring platelet reactivity in acute coronary syndrome: A plea for individualized antiplatelet treatment. International Journal of Cardiology, 2013, 167, 1794-1797.	0.8	11
266	Cardiovascular Pharmacology Core Reviews. Journal of Cardiovascular Pharmacology and Therapeutics, 2013, 18, 505-513.	1.0	12
267	Dual Antiplatelet Therapy Dilemmas: Duration and Choice of Antiplatelets in Acute Coronary Syndromes. Current Cardiology Reports, 2013, 15, 405.	1.3	5
268	Pharmacology of Antiplatelet Agents. Current Atherosclerosis Reports, 2013, 15, 371.	2.0	23
269	Comparison of Antiplatelet Effect and Safety of Clopidogrel Napadisilate with Clopidogrel Bisulfate in Coronary Artery Disease Patients: Multi-center, Randomized, Double-blind, Phase IV, Non-inferiority Clinical Trial. American Journal of Cardiovascular Drugs, 2013, 13, 413-424.	1.0	3
270	New Antiplatelet Agents and the Role of Platelet Function Testing in Acute Coronary Syndromes. Clinical Therapeutics, 2013, 35, 1064-1068.	1.1	8
271	Avoiding stent thrombosis: advances in technique, antiplatelet pharmacotherapy and stent design. Interventional Cardiology, 2013, 5, 179-201.	0.0	0
272	Platelet reactivity after coronary stenting. Lancet, The, 2013, 382, 583-584.	6.3	2
273	Incidence and Outcome of High On-Treatment Platelet Reactivity in Patients With Non-ST Elevation Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention (from the VIP) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 342 T 792-798.	0.7	12
274	Practical challenges in integrating genomic data into the electronic health record. Genetics in Medicine, 2013, 15, 772-778.	1.1	85
275	Pharmacogenomics in cardiovascular disease: focus on aspirin and ADP receptor antagonists. Journal of Thrombosis and Haemostasis, 2013, 11, 1627-1639.	1.9	28
276	Importance of measurement of platelet reactivity to ADP in patients with coronary artery disease: an historical account. Expert Review of Cardiovascular Therapy, 2013, 11, 1547-1556.	0.6	4
277	Assessing post-treatment platelet reactivity: a focus on patient selection and setting. Expert Review of Cardiovascular Therapy, 2013, 11, 1557-1566.	0.6	1
278	Incidence of Microemboli and Correlation with Platelet Inhibition in Aneurysmal Flow Diversion. American Journal of Neuroradiology, 2013, 34, 2321-2325.	1.2	14
279	Clinical Genome Sequencing. , 2013, , 102-122.		29
280	Platelet-Function Testing in Patients Undergoing Neurovascular Procedures: Caught between a Rock and a Hard Place. American Journal of Neuroradiology, 2013, 34, 730-734.	1.2	30

#	Article	IF	Citations
281	Differential prognostic impact of high on-treatment platelet reactivity among patients with acute coronary syndromes versus stable coronary artery disease undergoing percutaneous coronary intervention. American Heart Journal, 2013, 165, 34-42.e1.	1.2	39
282	Nonâ€“ST-Segment Elevation Acute Coronary Syndromes. , 2013, , 153-177.		0
283	Individualisation du traitement antiplaquettaire : quel est lâ€™intÃ©rÃªt du monitoring plaquettaire ?. Archives Des Maladies Du Coeur Et Des Vaisseaux - Pratique, 2013, 2013, 35-41.	0.0	0
284	Platelet Function and Genetic Testing. Journal of the American College of Cardiology, 2013, 62, S21-S31.	1.2	28
285	Pharmacological Interactions. JACC: Cardiovascular Interventions, 2013, 6, 180-181.	1.1	0
286	Almanac 2012: Interventional cardiology. Egyptian Heart Journal, 2013, 65, 31-41.	0.4	0
287	Nuisance and alarming bleeding do not correlate with on-treatment platelet reactivity. Cardiovascular Revascularization Medicine, 2013, 14, 76-80.	0.3	3
288	Variability of platelet responses to adenosine diphosphate. Thrombosis Research, 2013, 131, 472-473.	0.8	1
289	Triple Antithrombotic Therapy With Prasugrel in the Stented Patient. Journal of the American College of Cardiology, 2013, 61, 2067-2069.	1.2	1
290	Almanac 2012: Interventional cardiology. Revista Portuguesa De Cardiologia, 2013, 32, 447-457.	0.2	0
291	Impact of high post-loading platelet aggregation on 30-day clinical outcomes after primary percutaneous coronary intervention. The antiplatelet regimen tailoring after primary PCI (ART-PCI) trial. International Journal of Cardiology, 2013, 167, 1632-1637.	0.8	7
292	Value of platelet pharmacogenetics in common clinical practice of patients with ST-segment elevation myocardial infarction. International Journal of Cardiology, 2013, 167, 2882-2888.	0.8	27
293	Thienopyridine efficacy and cigarette smoking status. American Heart Journal, 2013, 165, 693-703.	1.2	12
294	Aspirin, Platelet P2Y12 Receptor Inhibitors, and Other Oral Antiplatelets. Interventional Cardiology Clinics, 2013, 2, 527-535.	0.2	8
295	Cuando la resistencia a los bloqueadores del receptor de adenosindifosfato centra toda la atenciÃ³n, Â¿la resistencia a la aspirina tiene algo que decir?. Revista Espanola De Cardiologia, 2013, 66, 311-312.	0.6	0
296	Evolving pattern of on-prasugrel and on-ticagrelor platelet reactivity over time in ST elevation myocardial infarction patients. International Journal of Cardiology, 2013, 168, 629-630.	0.8	9
297	Switching Acute Coronary Syndrome Patients From Prasugrel to Clopidogrel. JACC: Cardiovascular Interventions, 2013, 6, 158-165.	1.1	60
298	Pharmacogenomics in Interventional Pharmacology. Interventional Cardiology Clinics, 2013, 2, 615-625.	0.2	2

#	Article	IF	Citations
299	Degradable polymer drug-eluting stents: a durable benefit?. Lancet, The, 2013, 381, 607-609.	6.3	0
300	Platelet reactivity in the early and late phases of acute coronary syndromes according to cytochrome P450 2C19 phenotypes. Journal of Cardiology, 2013, 62, 158-164.	0.8	28
301	Elevated Plasma Fibrinogen Rather Than Residual Platelet Reactivity After Clopidogrel Pre-Treatment Is Associated With an Increased Ischemic Risk During Elective Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2013, 61, 23-34.	1.2	30
302	Almanac 2012: Interventional cardiology. Revista Portuguesa De Cardiologia (English Edition), 2013, 32, 447-457.	0.2	0
303	High-Dose Atorvastatin on the Pharmacodynamic Effects of Double-Dose Clopidogrel in Patients Undergoing Percutaneous Coronary Interventions. JACC: Cardiovascular Interventions, 2013, 6, 169-179.	1.1	23
304	Medical therapy of coronary artery disease after percutaneous intervention. Current Opinion in Pharmacology, 2013, 13, 287-293.	1.7	11
305	Triple Therapy With Aspirin, Prasugrel, and Vitamin K Antagonists in Patients With Drug-Eluting Stent Implantation and an Indication for Oral Anticoagulation. Journal of the American College of Cardiology, 2013, 61, 2060-2066.	1.2	225
306	Monitoring of Antiplatelet Therapy. , 2013, , 603-633.		2
308	ADP Receptor Antagonists. , 2013, , 1117-1138.		5
309	Mutational analysis clopidogrel resistance and platelet function in patients scheduled for coronary artery bypass grafting. Genomics, 2013, 101, 313-317.	1.3	5
310	Stent thrombosis and platelet reactivity. Cor Et Vasa, 2013, 55, e151-e157.	0.1	0
311	Dual antiplatelet therapy in patients with diabetes mellitus: special considerations. Expert Review of Cardiovascular Therapy, 2013, 11, 307-317.	0.6	6
312	Resistance to high-maintenance dose of prasugrel treated by ticagrelor: A case report. Platelets, 2013, 24, 239-241.	1.1	13
313	Pharmacotherapy for the reduction of stent thrombosis. Expert Review of Cardiovascular Therapy, 2013, 11, 567-576.	0.6	1
314	Monitoring Aspirin and Clopidogrel Response: Testing Controversies and Recommendations. Molecular Diagnosis and Therapy, 2013, 17, 123-137.	1.6	5
315	Platelet Function Monitoring and Clopidogrel. Current Cardiology Reports, 2013, 15, 321.	1.3	9
316	Antiplatelet and anticoagulant strategies in acute coronary syndrome: where we are in 2013. Future Cardiology, 2013, 9, 371-385.	0.5	0
317	ST-Segment Elevation Myocardial Infarction. , 2013, , 459-485.		0

#	Article	IF	Citations
318	Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events. New England Journal of Medicine, 2013, 368, 1303-1313.	13.9	695
319	Efficacy and safety of intensified antiplatelet therapy on the basis of platelet reactivity testing in patients after percutaneous coronary intervention: Systematic review and meta-analysis. International Journal of Cardiology, 2013, 167, 2140-2148.	0.8	113
320	Antiplatelet and Anticoagulant Therapy for Atherothrombotic Disease: The Role of Current and Emerging Agents. American Journal of Cardiovascular Drugs, 2013, 13, 233-250.	1.0	36
321	Viewpoint: Mismatch between the European and American guidelines on oral antiplatelet P2Y12 inhibitors after acute coronary syndromes. Thrombosis and Haemostasis, 2013, 110, 5-10.	1.8	15
322	Clopidogrel Resistance Is Associated with Thromboembolic Complications in Patients Undergoing Neurovascular Stenting. American Journal of Neuroradiology, 2013, 34, 716-720.	1.2	134
323	Pharmacokinetic considerations for antithrombotic therapies in stroke. Expert Opinion on Drug Metabolism and Toxicology, 2013, 9, 1335-1347.	1.5	4
324	Antiplatelet therapy: new pharmacological agents and changing paradigms. Journal of Thrombosis and Haemostasis, 2013, 11, 316-329.	1.9	61
325	Ticlopidine with Ginkgo Biloba extract: A Feasible Combination for Patients with Acute Cerebral Ischemia. Thrombosis Research, 2013, 131, e147-e153.	0.8	14
326	Effects of VerifyNow P2Y12 test and CYP2C19*2 testing on clinical outcomes of patients with cardiovascular disease: A systematic review and meta-analysis. Platelets, 2013, 24, 352-361.	1.1	35
327	Impact of CYP2C19 Genetic Testing on Provider Prescribing Patterns for Antiplatelet Therapy After Acute Coronary Syndromes and Percutaneous Coronary Intervention. Circulation: Cardiovascular Quality and Outcomes, 2013, 6, 694-699.	0.9	14
328	2013 ESC guidelines on the management of stable coronary artery disease. European Heart Journal, 2013, 34, 2949-3003.	1.0	3,915
329	General Considerations for Neurointerventional Procedures. , 2013, , 153-185.		1
330	Mismatch between the European and American guidelines on oral antiplatelet P2Y12 inhibitors after acute coronary syndromes. European Heart Journal, 2013, 34, P2510-P2510.	1.0	0
331	Effect of antiplatelet therapy on thromboembolism after flow diversion with the Pipeline Embolization Device. Journal of Neurosurgery, 2013, 119, 1603-1610.	0.9	58
332	Impaired platelet P2Y12 inhibition by thienopyridines in chronic kidney disease: mechanisms, clinical relevance and pharmacological options. Nephrology Dialysis Transplantation, 2013, 28, 1994-2002.	0.4	36
333	Antiplatelet therapy strategies after percutaneous coronary intervention in patients needing oral anticoagulation. Future Cardiology, 2013, 9, 759-762.	0.5	0
334	Assessment of Platelet Inhibition by Point-of-Care Testing in Neuroendovascular Procedures. American Journal of Neuroradiology, 2013, 34, 700-706.	1.2	21
335	Risk Factors for Coronary Drug-Eluting Stent Thrombosis: Influence of Procedural, Patient, Lesion, and Stent Related Factors and Dual Antiplatelet Therapy. ISRN Cardiology, 2013, 2013, 1-8.	1.6	18

#	Article	IF	Citations
336	Historical Lessons in Translational Medicine. Circulation Research, 2013, 112, 174-194.	2.0	38
337	Treatment Options for Patients With Poor Clopidogrel Response. Cardiology in Review, 2013, 21, 309-317.	0.6	10
338	The role of clopidogrel in the management of ischemic heart disease. Current Opinion in Cardiology, 2013, 28, 381-388.	0.8	0
339	Potential clinical utility of genetic and platelet function tests in patients on treatment with clopidogrel. Journal of Cardiovascular Medicine, 2013, 14, S16-S21.	0.6	4
340	Prasugrel. Circulation: Cardiovascular Quality and Outcomes, 2013, 6, 253-254.	0.9	4
341	Point of care platelet function testing in routine neurointerventional care is unjustified. Journal of NeuroInterventional Surgery, 2013, 5, 280-282.	2.0	7
342	Should Platelet Function Testing Guide Antiplatelet Therapy for Patients with Coronary Artery Stenting or Acute Coronary Syndromes?. Clinical Chemistry, 2013, 59, 1299-1300.	1.5	4
343	Clopidogrel, Prasugrel, or Ticagrelor? A Practical Guide to Use of Antiplatelet Agents in Patients With Acute Coronary Syndromes. Postgraduate Medicine, 2013, 125, 91-102.	0.9	41
344	Relationship between aspirin/clopidogrel resistance and intra-stent thrombi assessed by follow-up optical coherence tomography after drug-eluting stent implantation. European Heart Journal Cardiovascular Imaging, 2013, 14, 1181-1186.	0.5	9
346	Role of CYP450 in Antiplatelet Therapy: Considerations for Patients at Risk for Further Cardiovascular or Cerebrovascular Problems. Journal of Pharmacy Technology, 2013, 29, 72-87.	0.5	0
347	Identifying responsiveness to oral P2Y12 receptor blockers. Journal of Cardiovascular Medicine, 2013, 14, S8-S15.	0.6	4
348	Effects of Endothelial Dysfunction on Residual Platelet Aggregability After Dual Antiplatelet Therapy With Aspirin and Clopidogrel in Patients With Stable Coronary Artery Disease. Circulation: Cardiovascular Interventions, 2013, 6, 452-459.	1.4	21
349	Tailored Thienopyridine Therapy: No Urgency for CYP2C19 Genotyping. Journal of the American Heart Association, 2013, 2, e000131.	1.6	20
350	Clopidogrel and warfarin pharmacogenetic tests. Current Opinion in Cardiology, 2013, 28, 305-314.	0.8	15
351	Cross-modulatory effects of clopidogrel and heparin on platelet and fibrin incorporation in thrombosis. Blood Coagulation and Fibrinolysis, 2013, 24, 593-598.	0.5	11
352	ARCTIC: Additional proof against antiplatelet adjusted therapy. Global Cardiology Science & Practice, 2013, 2013, 17.	0.3	2
353	The CYP2C19*1/*2 Genotype Does Not Adequately Predict Clopidogrel Response in Healthy Malaysian Volunteers. Cardiology Research and Practice, 2013, 2013, 1-7.	0.5	11
354	Changes in antiplatelet use prior to incident ischaemic stroke over 7 years in a UK centre and the association with stroke subtype. Age and Ageing, 2013, 42, 594-598.	0.7	11

#	Article	IF	Citations
355	The Utility of Platelet and Coagulation Testing of Antithrombotics: Fusing Science with Patient Care. Drug Development Research, 2013, 74, 587-593.	1.4	6
356	Hematocrit alters VerifyNow P2Y12 assay results independently of intrinsic platelet reactivity and clopidogrel responsiveness. Journal of Thrombosis and Haemostasis, 2013, 11, 1814-1822.	1.9	47
357	Recommendations for the standardization of light transmission aggregometry: a consensus of the working party from the platelet physiology subcommittee of SSC/ISTH. Journal of Thrombosis and Haemostasis, 2013, 11, 1183-1189.	1.9	398
358	Role of Thrombelastography (<scp>TEG</scp>) in Risk Assessment and Guidance of Antithrombotic Therapy in Patients with Coronary Artery Disease. Drug Development Research, 2013, 74, 533-540.	1.4	5
359	Use of antiplatelet drugs in stroke prevention: time for a rethink?. Postgraduate Medical Journal, 2013, 89, 309-310.	0.9	3
360	Antiplatelet testing in neurointervention: we cannot ignore the signs. Journal of NeuroInterventional Surgery, 2013, 5, 277-279.	2.0	11
361	Comparison of On-Treatment Platelet Reactivity Between Triple Antiplatelet Therapy With Cilostazol and Standard Dual Antiplatelet Therapy in Patients Undergoing Coronary Interventions. Journal of Cardiovascular Pharmacology and Therapeutics, 2013, 18, 533-543.	1.0	8
362	Pharmacogenomics of anti-platelet therapy: how much evidence is enough for clinical implementation?. Journal of Human Genetics, 2013, 58, 339-345.	1.1	28
363	Identifying determinants of variability to tailor aspirin therapy. Expert Review of Cardiovascular Therapy, 2013, 11, 365-379.	0.6	23
364	Tailoring Antiplatelet Therapy. Circulation Journal, 2013, 77, 1150-1151.	0.7	0
365	Personalized antiplatelet therapy in acute coronary syndromes: a dead-end street or a future scenario?. Interventional Cardiology, 2013, 5, 601-604.	0.0	0
366	High platelet reactivity â€“ the challenge of prolonged anticoagulation therapy after ACSI. Thrombosis and Haemostasis, 2013, 109, 799-807.	1.8	5
367	Identification of poor response to P2Y12 inhibitors in ACS patients with a new ELISA-based vasodilator-associated stimulated phosphoprotein (VASP) phosphorylation assay. Thrombosis and Haemostasis, 2013, 110, 1055-1064.	1.8	10
368	Differences in high on-treatment platelet reactivity between intracoronary and peripheral blood after dual anti-platelet agents in patients with coronary artery disease. Thrombosis and Haemostasis, 2013, 110, 124-130.	1.8	4
369	High on-treatment platelet reactivity â€“ definition and measurement. Thrombosis and Haemostasis, 2013, 109, 792-798.	1.8	41
370	Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: Insights from the switching anti-platelet (SWAP) study. Thrombosis and Haemostasis, 2013, 109, 347-355.	1.8	19
371	Measuring Platelet Reactivity after Clopidogrel-Has it Reached the End of the Road?. Cardiovascular Pharmacology: Open Access, 2013, 2, .	0.1	4
372	Genotype- and Phenotype-Directed Personalization of Antiplatelet Treatment in Patients with Non-ST Elevation Acute Coronary Syndromes Undergoing Coronary Stenting. Korean Circulation Journal, 2013, 43, 541.	0.7	12

#	Article	IF	Citations
373	Efficacy and Safety of Platelet Inhibitors. Journal of Pharmacy and Pharmaceutical Sciences, 2013, 16, 1.	0.9	10
374	Successful Prasugrel Rescue Therapy in Clopidogrel Resistant Patients Who Had Recurrent Stent Thrombosis of Drug-Eluting-Stent: The Role of Prasugrel in Clopidogrel Nonresponders. Korean Circulation Journal, 2013, 43, 343.	0.7	2
375	High on-treatment platelet reactivity and P2Y12 antagonists in clinical trials. Thrombosis and Haemostasis, 2013, 109, 834-845.	1.8	28
376	Why have studies of tailored anti-platelet therapy failed so far?. Thrombosis and Haemostasis, 2013, 110, 628-631.	1.8	27
377	High-Maintenance-Dose Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis. PLoS ONE, 2013, 8, e78549.	1.1	7
378	Platelet function testing and prediction of procedural bleeding risk. Thrombosis and Haemostasis, 2013, 109, 817-824.	1.8	30
379	Advances in antiplatelet technologies to improve cardiovascular disease morbidity and mortality: a review of ticagrelor. Clinical Pharmacology: Advances and Applications, 2013, 5, 67.	0.8	4
380	Hemostatic Aspects of Cardiovascular Medicine. , 2013, , 342-394.		0
381	Different Influences of Hematocrit on the Results of Two Point-Of-Care Platelet Function Tests, the VerifyNow Assay and Multiple Electrode Platelet Aggregometry. PLoS ONE, 2014, 9, e114053.	1.1	24
382	Discontinuing clopidogrel: Abrupt or tapered cessation?. Thrombosis and Haemostasis, 2014, 111, 1007-1008.	1.8	0
383	Comparison of P2Y12 receptor inhibition by clopidogrel and prasugrel in patients undergoing percutaneous coronary intervention. Bangladesh Medical Research Council Bulletin, 2014, 39, 139-145.	0.1	2
384	Optimising pharmacotherapy for secondary prevention of nonâ€invasively managed acute coronary syndrome. Medical Journal of Australia, 2014, 201, S100-5.	0.8	1
385	The impact of renal function on platelet reactivity and clinical outcome in patients undergoing percutaneous coronary intervention with stenting. Thrombosis and Haemostasis, 2014, 112, 1174-1181.	1.8	28
386	Direct oral anticoagulants and antiplatelet agents. Hamostaseologie, 2014, 34, 78-84.	0.9	16
387	Monitoring ASA and P2Y12-specific platelet inhibition â€“ comparison of conventional (single) and multiple electrode aggregometry. Scandinavian Journal of Clinical and Laboratory Investigation, 2014, 74, 568-574.	0.6	6
388	A Review of the Role of Electronic Health Record in Genomic Research. Journal of Cardiovascular Translational Research, 2014, 7, 692-700.	1.1	18
389	A high ratio of ADPâ€“TRAP induced platelet aggregation is associated more strongly with increased mortality after coronary stent implantation than high conventional ADP induced aggregation alone. Clinical Research in Cardiology, 2014, 103, 968-975.	1.5	10
390	A platelet P-selectin test predicts adverse cardiovascular events in patients with acute coronary syndromes treated with aspirin and clopidogrel. Platelets, 2014, 25, 612-618.	1.1	26

#	Article	IF	Citations
391	A Freeze on Tailored Antiplatelet Therapy?. Circulation, 2014, 129, 2088-2090.	1.6	1
392	Pharmacogenomics of Clopidogrel. , 2014, , 509-541.		1
393	Genotype- and phenotype-directed antiplatelet therapy selection in patients with acute coronary syndromes. Expert Review of Cardiovascular Therapy, 2014, 12, 1289-1303.	0.6	4
394	The Prognostic Impact of High On-Treatment Platelet Reactivity with Aspirin or ADP Receptor Antagonists: Systematic Review and Meta-Analysis. BioMed Research International, 2014, 2014, 1-13.	0.9	16
395	Combination of high on-treatment platelet aggregation and low deaggregation better predicts long-term cardiovascular events in PCI patients under dual antiplatelet therapy. Platelets, 2014, 25, 439-446.	1.1	4
396	Point-of-care assessment of platelet reactivity in the emergency department may facilitate rapid rule-out of acute coronary syndromes: a prospective cohort pilot feasibility study. BMJ Open, 2014, 4, e003883.	0.8	7
397	Neurointerventional Stenting and Antiplatelet Function Testing: To Do or Not to Do?. Interventional Neurology, 2014, 3, 184-189.	1.8	11
398	Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. European Heart Journal, 2014, 35, 209-215.	1.0	224
400	2014 ESC/EACTS Guidelines on myocardial revascularization. European Journal of Cardio-thoracic Surgery, 2014, 46, 517-592.	0.6	2,164
401	Impact of Gene Polymorphisms, PlateletÂReactivity, and the SYNTAX Score on 1-Year Clinical Outcomes in PatientsÂWithÂNonâ€“ST-Segment Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2014, 7, 1117-1127.	1.1	38
402	World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI. Nature Reviews Cardiology, 2014, 11, 597-606.	6.1	267
403	Predictors and Outcomes of Recurrent Stent Thrombosis. JACC: Cardiovascular Interventions, 2014, 7, 1105-1113.	1.1	24
404	New Antithrombotics for Secondary Prevention of Acute Coronary Syndrome. Clinical Cardiology, 2014, 37, 178-187.	0.7	20
405	Point-of-care Measurements of Platelet Inhibition After Clopidogrel Loading in Patients With Acute Coronary Syndrome: Comparison of Generic and Branded Clopidogrel Bisulfate. Clinical Therapeutics, 2014, 36, 1588-1594.	1.1	6
406	Plateletâ€reactivity tests identify patients at risk of secondary cardiovascular events: a systematic review and metaâ€analysis. Journal of Thrombosis and Haemostasis, 2014, 12, 736-747.	1.9	83
407	Detecting a thienopyridine effect by platelet reactivity assessment and its implications for risk stratification. Journal of Thrombosis and Haemostasis, 2014, 12, 560-563.	1.9	4
409	Individualising dual antiplatelet therapy after percutaneous coronary intervention: the IDEAL-PCI registry. BMJ Open, 2014, 4, e005781.	0.8	21
410	2014 AHA/ACC Guideline for the Management of Patients With Nonâ€“ST-Elevation Acute Coronary Syndromes. Circulation, 2014, 130, e344-426.	1.6	928

#	Article	IF	Citations
411	Tailored antiplatelet therapy and clinical adverse outcomes. Heart, 2014, 100, 41-46.	1.2	12
413	Carotid artery stenting outcomes: do they correlate with antiplatelet response assays?. Journal of NeuroInterventional Surgery, 2014, 6, 373-378.	2.0	29
414	Pharmacodynamic and Clinical Implications of Switching Between P2Y12 Receptor Antagonists. Critical Pathways in Cardiology, 2014, 13, 156-158.	0.2	9
415	Improved Ticagrelor Antiplatelet Effect on Discontinuation of Phenytoin. Annals of Pharmacotherapy, 2014, 48, 644-647.	0.9	5
416	Variability of on-treatment platelet reactivity in patients on clopidogrel. Platelets, 2014, 25, 328-336.	1.1	18
417	Platelet function inhibitors and platelet function testing in neurointerventional procedures: TableÂ1. Journal of NeuroInterventional Surgery, 2014, 6, 567-577.	2.0	37
418	Microfluidic Thrombosis under Multiple Shear Rates and Antiplatelet Therapy Doses. PLoS ONE, 2014, 9, e82493.	1.1	65
419	Efficacy of cilostazol on platelet reactivity and cardiovascular outcomes in patients undergoing percutaneous coronary intervention: insights from a meta-analysis of randomised trials. Open Heart, 2014, 1, e000068.	0.9	39
420	Prasugrel and ticagrelor. Journal of Cardiovascular Medicine, 2014, 15, 8-18.	0.6	4
421	Prognostic Role of Platelet Reactivity in Patients With Acute Coronary Syndromes. Cardiology in Review, 2014, 22, 313-318.	0.6	6
422	Thresholds for platelet reactivity to predict clinical events after coronary intervention are different in patients with and without diabetes mellitus. Platelets, 2014, 25, 348-356.	1.1	17
423	Single antiplatelet therapy after percutaneous coronary intervention in patients allergic to aspirin. Cardiovascular Revascularization Medicine, 2014, 15, 308-310.	0.3	5
424	Risk of Stroke in Patients With High On-Clopidogrel Platelet Reactivity to Adenosine Diphosphate After Percutaneous Coronary Intervention. American Journal of Cardiology, 2014, 113, 1807-1814.	0.7	5
425	Thrombotic and bleeding events after coronary stenting according to clopidogrel and aspirin platelet reactivity: VerifyNow French Registry (VERIFRENCHY). Archives of Cardiovascular Diseases, 2014, 107, 225-235.	0.7	12
426	CYP2C19 genotypeâ€“guided antiplatelet therapy in ST-segment elevation myocardial infarction patientsâ€”Rationale and design of the Patient Outcome after primary PCI (POPular) Genetics study. American Heart Journal, 2014, 168, 16-22.e1.	1.2	71
427	Pharmacodynamic effects of adjunctive high dose atorvastatin on double dose clopidogrel in patients with high on-treatment platelet reactivity depending on diabetes mellitus status. Journal of Thrombosis and Thrombolysis, 2014, 37, 427-434.	1.0	7
428	Impact of new oral or intravenous P2Y12 inhibitors and clopidogrel on major ischemic and bleeding events in patients with coronary artery disease: A meta-analysis of randomized trials. Atherosclerosis, 2014, 233, 568-578.	0.4	21
429	Lessons Learned from Negative Clinical Trials Evaluating Antithrombotic Therapy for Ischemic Heart Disease. Journal of Cardiovascular Translational Research, 2014, 7, 112-125.	1.1	0

#	Article	IF	Citations
430	Optimizing P2Y12 Receptor Inhibition in Patients With Acute Coronary Syndrome on the Basis of Platelet Function Testing. Journal of the American College of Cardiology, 2014, 63, 1061-1070.	1.2	81
431	Relationship between changes in platelet reactivity and ischemicÂevents following percutaneous coronary intervention: AÂmeta-regression analysis of 30 randomized trials. Atherosclerosis, 2014, 234, 176-184.	0.4	16
432	The use of platelet function testing in PCI and CABG patients. Blood Reviews, 2014, 28, 109-121.	2.8	17
433	Differences in thrombus structure and kinetics in patients with type 2 diabetes mellitus after non ST elevation acute coronary syndrome. Thrombosis Research, 2014, 133, 880-885.	0.8	13
434	New antiplatelet agents in the treatment of acute coronary syndromes. Archives of Cardiovascular Diseases, 2014, 107, 178-187.	0.7	14
435	High On-Treatment Platelet Reactivity as a Risk Factor for Secondary Prevention After Coronary Stent Revascularization. Circulation, 2014, 129, 2136-2143.	1.6	46
436	Prasugrel or double-dose clopidogrel to overcome clopidogrel low-response â€“ The TAILOR (Thrombocytes And IndividuaLization of ORal antiplatelet therapy in percutaneous coronary) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 497 T		
437	Impact of Obesity and the Metabolic Syndrome on Response to Clopidogrel or Prasugrel and Bleeding Risk in Patients Treated After Coronary Stenting. American Journal of Cardiology, 2014, 113, 54-59.	0.7	35
438	P2Y12 Receptor Inhibitors in Acute Coronary Syndromes: From the Research Laboratory to the Clinic and Vice Versa. Cardiology, 2014, 127, 211-219.	0.6	14
439	Clopidogrel resistance: The way forward. Indian Heart Journal, 2014, 66, 530-534.	0.2	51
440	Association of Immature Platelets With Adverse Cardiovascular Outcomes. Journal of the American College of Cardiology, 2014, 64, 2122-2129.	1.2	131
441	Role of phenotypic and genetic testing in managing clopidogrel therapy. Blood, 2014, 124, 689-699.	0.6	28
442	The Sum of Two Evils. Journal of the American College of Cardiology, 2014, 64, 1926-1928.	1.2	39
443	Platelet function monitoring in elderly patients on prasugrel after stenting for an acute coronary syndrome: Design of the randomized antarctic study. American Heart Journal, 2014, 168, 674-681.e1.	1.2	21
444	Superiority of Ticagrelor Over Clopidogrel in Patients After Cardiac Arrest Undergoing Therapeutic Hypothermia. Canadian Journal of Cardiology, 2014, 30, 1396-1399.	0.8	21
445	Global platelet hyperreactivity and elevated C-reactive protein levels predict long term mortality in STEMI patients. Thrombosis Research, 2014, 134, 884-888.	0.8	16
446	Diabetes Mellitus and Clopidogrel Response Variabilityâ^—. Journal of the American College of Cardiology, 2014, 64, 1015-1018.	1.2	8
448	Clopidogrel dose adjustment after outpatient screening for CYP2C19 variant alleles: a pilot study. Pharmacogenomics, 2014, 15, 915-923.	0.6	9

#	Article	IF	Citations
449	Role of genetic factors on the effect of additional loading doses and two maintenance doses used to overcome clopidogrel hyporesponsiveness. Medicina (Lithuania), 2014, 50, 19-27.	0.8	3
450	Strategies to Reduce Bleeding Risk in Acute Coronary Syndromes and Percutaneous Coronary Intervention: New and Emerging Pharmacotherapeutic Considerations. Pharmacotherapy, 2014, 34, 973-990.	1.2	2
451	Does baseline hematocrit influence the assays of on-treatment platelet reactivity to clopidogrel?. American Heart Journal, 2014, 168, 545-551.	1.2	12
453	The Chronovariability of Platelet Reactivity. Journal of the American College of Cardiology, 2014, 64, 369-371.	1.2	0
454	Variability of Individual Platelet ReactivityÂOver Time in Patients TreatedÂWith Clopidogrel. Journal of the American College of Cardiology, 2014, 64, 361-368.	1.2	70
455	2014 ESC/EACTS Guidelines on myocardial revascularization. European Heart Journal, 2014, 35, 2541-2619.	1.0	4,141
456	Clinical pharmacogenetics implementation: Approaches, successes, and challenges. American Journal of Medical Genetics, Part C: Seminars in Medical Genetics, 2014, 166, 56-67.	0.7	162
459	2014 AHA/ACC Guideline for theÂManagement of Patients WithÂNonâ€“ST-Elevation Acute Coronary Syndromes. Journal of the American College of Cardiology, 2014, 64, e139-e228.	1.2	2,746
460	Poor agreement between light transmission aggregometry, Verify Now P2Y12and vasodilatator-stimulated phosphoprotein for clopidogrel low-response assessment: A potential explanation of negative results of recent randomized trials. Platelets, 2014, 25, 499-505.	1.1	25
461	High on clopidogrel treatment platelet reactivity is frequent in acute and rare in elective stenting and can be functionally overcome by switch of therapy. Thrombosis Research, 2014, 133, 257-264.	0.8	10
462	Recent advances in antithrombotic therapy after acute coronary syndrome. Cmaj, 2014, 186, 589-596.	0.9	4
463	Factor XIII Val34Leu polymorphism and recurrent myocardial infarction in patients with coronary artery disease. Journal of Thrombosis and Thrombolysis, 2014, 38, 380-387.	1.0	14
464	Serial clopidogrel dose adjustment after platelet function testing improves outcome of acute coronary syndrome patients undergoing percutaneous coronary intervention with high on-treatment platelet reactivity. Journal of Thrombosis and Thrombolysis, 2014, 38, 459-469.	1.0	18
465	Effectiveness of clopidogrel dose escalation to normalize active metabolite exposure and antiplatelet effects in CYP2C19 poor metabolizers. Journal of Clinical Pharmacology, 2014, 54, 865-873.	1.0	31
467	Resistance to antiplatelet drugs: what progress has been made?. Expert Opinion on Pharmacotherapy, 2014, 15, 2553-2564.	0.9	30
468	Antiplatelet and anticoagulation agents in acute coronary syndromes: What is the current status and what does the future hold?. American Heart Journal, 2014, 168, 611-621.	1.2	34
469	II. Looking into the future of platelet transfusion in the presence of P2Y12 inhibitors. British Journal of Anaesthesia, 2014, 112, 780-784.	1.5	7
470	Antiplatelet effects of clopidogrel dose adjustment (75Âmg/d vs 150Âmg/d) after carotid stenting. Journal of Vascular Surgery, 2014, 60, 428-435.	0.6	12

#	Article	IF	Citations
471	Tratamiento antiagregante plaquetario personalizado. Revista Espanola De Cardiologia, 2014, 67, 480-487.	0.6	10
473	Impact of new P2Y12 blockers on platelet reactivity and clinical outcomes after acute coronary syndrome: Insight from a large single center registry. International Journal of Cardiology Heart & Vessels, 2014, 4, 188-192.	0.5	4
474	The effect of doubling the dose of clopidogrel on platelet aggregation in patients with clopidogrel resistance. Egyptian Heart Journal, 2014, 66, 259-262.	0.4	2
475	Personalized Antiplatelet Therapy. Revista Espanola De Cardiologia (English Ed), 2014, 67, 480-487.	0.4	1
476	Pharmacokinetic evaluation of prasugrel for the treatment of myocardial infarction. Expert Opinion on Drug Metabolism and Toxicology, 2014, 10, 609-620.	1.5	3
477	Pharmacogenetics of Antiplatelet Therapy. Current Atherosclerosis Reports, 2014, 16, 411.	2.0	2
478	Front-loading with clopidogrel plus aspirin followed by dual antiplatelet therapy in the prevention of early stroke recurrence. Expert Review of Neurotherapeutics, 2014, 14, 723-734.	1.4	0
479	Expert position paper on the management of antiplatelet therapy in patients undergoing coronary artery bypass graft surgery. European Heart Journal, 2014, 35, 1510-1514.	1.0	70
480	Charting a Roadmap for Heart Failure Biomarker Studies. JACC: Heart Failure, 2014, 2, 477-488.	1.9	81
481	Platelet Function Testing in Contemporary Clinical and Interventional Practice. Current Treatment Options in Cardiovascular Medicine, 2014, 16, 300.	0.4	34
482	Universal versus platelet reactivity assay-driven use of P2Y12 inhibitors in acute coronary syndrome patients. Thrombosis and Haemostasis, 2014, 111, 103-110.	1.8	7
483	A comparative cohort study on personalised antiplatelet therapy in PCI-treated patients with high on-clopidogrel platelet reactivity. Thrombosis and Haemostasis, 2014, 112, 342-351.	1.8	41
484	Transferring from clopidogrel loading dose to prasugrel loading dose in acute coronary syndrome patients. Thrombosis and Haemostasis, 2014, 112, 311-322.	1.8	7
485	A model-based analysis of the clinical and economic impact of personalising P2Y12-receptor inhibition with platelet function testing in acute coronary syndrome patients. Thrombosis and Haemostasis, 2014, 112, 290-299.	1.8	24
486	Cost-Effectiveness of Genotype-Guided and Dual Antiplatelet Therapies in Acute Coronary Syndrome. Annals of Internal Medicine, 2014, 160, 221-232.	2.0	84
488	Antiplatelet Therapy in Patients With Diabetes Mellitus and Acute Coronary Syndrome. Circulation Journal, 2014, 78, 33-41.	0.7	22
489	Pharmacodynamic Comparison of Pitavastatin Versus Atorvastatin on Platelet Reactivity in Patients With Coronary Artery Disease Treated With Dual Antiplatelet Therapy. Circulation Journal, 2014, 78, 679-684.	0.7	13
490	New Insights for Low Dosing With the New P2Y₁₂ Inhibitors. Circulation Journal, 2014, 78, 2840-2842.	0.7	2

#	Article	IF	Citations
491	Characterization of Patients With Angioscopically-Detected In-Stent Mural Thrombi. Circulation Journal, 2014, 79, 85-90.	0.7	14
492	Does the VerifyNow P2Y12 assay overestimate â€œtherapeutic responseâ€•to clopidogrel?. Thrombosis and Haemostasis, 2014, 111, 1150-1159.	1.8	14
493	What is the meaning of P2Y12 reaction units in patients with essential thrombocythemia?. Journal of Cardiology Cases, 2015, 12, 205-207.	0.2	0
494	Contemporary use of platelet function and pharmacogenomic testing among patients with acute myocardial infarction undergoing percutaneous coronary intervention in the United States. American Heart Journal, 2015, 170, 706-714.	1.2	5
495	Ticagrelor overcomes high platelet reactivity in patients with acute myocardial infarction or coronary artery in-stent restenosis: a randomized controlled trial. Scientific Reports, 2015, 5, 13789.	1.6	19
496	How to improve the concept of individualised antiplatelet therapy with P2Y12 receptor inhibitors â€“ is an algorithm the answer?. Thrombosis and Haemostasis, 2015, 113, 37-52.	1.8	43
497	Personalized Antiplatelet Therapy Following Endovascular Revascularization in Peripheral Artery Occlusive Disease: A Novel Concept. EJVES Short Reports, 2015, 29, 11-17.	0.7	2
498	Resistance to antiplatelet drugs. Can it be assessed?. IJC Metabolic & Endocrine, 2015, 8, 31-33.	0.5	2
499	No association between on-treatment platelet reactivity and bleeding events following percutaneous coronary intervention and antiplatelet therapy: A post hoc analysis. Thrombosis Research, 2015, 136, 947-954.	0.8	9
500	2015 ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-segment Elevation. Revista Espanola De Cardiologia (English Ed), 2015, 68, 1125.	0.4	57
501	Utility of magnetoâ€electropolished ternary nitinol alloys for blood contacting applications. Journal of Biomedical Materials Research - Part B Applied Biomaterials, 2015, 103, 1366-1374.	1.6	5
502	Intrinsic platelet reactivity before start with clopidogrel as predictor for on-clopidogrel platelet function and long-term clinical outcome. Thrombosis and Haemostasis, 2015, 114, 109-114.	1.8	7
503	Antiplatelet drugs in patients with enhanced platelet turnover: biomarkers versus platelet function testing. Thrombosis and Haemostasis, 2015, 114, 459-468.	1.8	50
504	Platelet function testing in acute cardiac care â€“ is there a role for prediction or prevention of stent thrombosis and bleeding?. Thrombosis and Haemostasis, 2015, 113, 221-230.	1.8	33
505	Prevalence and Impact of High Platelet Reactivity in Chronic Kidney Disease. Circulation: Cardiovascular Interventions, 2015, 8, e001683.	1.4	65
506	High maintenance dose of clopidogrel in patients with high on-treatment platelet reactivity after a percutaneous coronary intervention. Coronary Artery Disease, 2015, 26, 386-395.	0.3	4
507	CYP2C19 genotype plus platelet reactivity-guided antiplatelet therapy in acute coronary syndrome patients. Pharmacogenetics and Genomics, 2015, 25, 609-617.	0.7	14
508	Low Onâ€Treatment Platelet Reactivity Predicts Longâ€Term Risk of Bleeding After Elective PCI. Journal of Interventional Cardiology, 2015, 28, 531-543.	0.5	3

#	Article	IF	Citations
509	Outcomes following implantation of the biolimus A9â€eluting Bio<scp>M</scp>atrix coronary stent: Primary analysis of the eâ€<scp>B</scp>io<scp>M</scp>atrix registry. Catheterization and Cardiovascular Interventions, 2015, 86, 1151-1160.	0.7	13
510	Optimizing clopidogrel dose response: a new clinical algorithm comprising CYP2C19 pharmacogenetics and drug interactions. Therapeutics and Clinical Risk Management, 2015, 11, 1421.	0.9	14
511	P2Y12 inhibitors for acute coronary syndromes: current perspectives. Research Reports in Clinical Cardiology, 2015, , 123.	0.2	0
512	Personalized antiplatelet therapy with P2Y 12 receptor inhibitors: benefits and pitfalls. Postepy W Kardiologii Interwencyjnej, 2015, 4, 259-280.	0.1	23
513	Impact of Sex and Gender on the Efficacy of Antiplatelet Therapy: The Female Perspective. Journal of Atherosclerosis and Thrombosis, 2015, 22, 109-125.	0.9	16
514	Temporal variability in the antiplatelet effects of clopidogrel and aspirin after elective drug-eluting stent implantation. Thrombosis and Haemostasis, 2015, 114, 1020-1027.	1.8	14
515	Evaluation of Clinical Risk Factors to Predict High On-Treatment Platelet Reactivity and Outcome in Patients with Stable Coronary Artery Disease (PREDICT-STABLE). PLoS ONE, 2015, 10, e0121620.	1.1	36
516	Genes and Cardiovascular Disease: Where do we go from here?. Sultan Qaboos University Medical Journal, 2015, 15, e448-e451.	0.3	2
517	An Assay of Measuring Platelet Reactivity Using Monoclonal Antibody against Activated Platelet Glycoprotein IIb/IIIa in Patients Taking Clopidogrel. Korean Circulation Journal, 2015, 45, 378.	0.7	6
518	Individualised dual antiplatelet therapy in a patient with short bowel syndrome after acute myocardial infarction with coronary artery stenting. BMJ Case Reports, 2015, 2015, bcr2014205227.	0.2	5
519	Is Platelet Transfusion Effective in Patients Taking Antiplatelet Agents Who Suffer an Intracranial Hemorrhage?. Journal of Emergency Medicine, 2015, 49, 561-572.	0.3	30
520	Association of dual-antiplatelet therapy with reduced major adverse cardiovascular events in patients with symptomatic peripheral arterial disease. Journal of Vascular Surgery, 2015, 62, 157-165.e1.	0.6	62
521	Antiplatelet Therapy Considerations in Ischemic Cardiogenic Shock. Journal of Cardiovascular Pharmacology and Therapeutics, 2015, 20, 370-377.	1.0	13
522	Platelet Function Testâ€"Guided Strategy. Circulation: Cardiovascular Interventions, 2015, 8, e002716.	1.4	1
523	Standard vs Modified Antiplatelet Preparation for Preventing Thromboembolic Events in Patients With High On-Treatment Platelet Reactivity Undergoing Coil Embolization for an Unruptured Intracranial Aneurysm. JAMA Neurology, 2015, 72, 764.	4.5	84
524	Dual Antiplatelet Therapy in Acute Ischemic Stroke. Current Atherosclerosis Reports, 2015, 17, 37.	2.0	5
525	Comparison of therapy with Ticagrelor, Prasugrel or high Clopidogrel dose in PCI patients with high on treatment platelet reactivity and genotype variation. TRIPLETE RESET trial. International Journal of Cardiology, 2015, 194, 60-62.	0.8	16
526	Novel Oral P2Y12 Inhibitor Prasugrel vs. Clopidogrel in Patients with Acute Coronary Syndrome: Evidence Based on 6 Studies. Medical Science Monitor, 2015, 21, 1131-1137.	0.5	4

#	Article	IF	Citations
527	Coming safely to a stop: a review of platelet activity after cessation of antiplatelet drugs. Therapeutic Advances in Drug Safety, 2015, 6, 141-150.	1.0	19
528	The future of P2Y₁₂ receptor antagonists. Platelets, 2015, 26, 392-398.	1.1	12
529	Chinese experts recommendation on the monitoring and management of variability in responsiveness to antiplatelet therapy. European Heart Journal Supplements, 2015, 17, B5-B12.	0.0	0
530	Proteomic signatures of antiplatelet drugs: new approaches to exploring drug effects. Journal of Thrombosis and Haemostasis, 2015, 13, S323-S331.	1.9	21
531	Pointâ€ofâ€Care Platelet Function Testing Predicts Bleeding in Patients Exposed to Clopidogrel Undergoing Coronary Artery Bypass Grafting: Verify Preâ€Op <scp>TIMI</scp> 45â€"A Pilot Study. Clinical Cardiology, 2015, 38, 92-98.	0.7	45
532	Is There an Ideal Level of Platelet P2Y12-Receptor Inhibition in PatientsÂUndergoing Percutaneous Coronary Intervention?. JACC: Cardiovascular Interventions, 2015, 8, 1978-1987.	1.1	31
533	P2Y12 receptors: structure and function. Journal of Thrombosis and Haemostasis, 2015, 13, S10-S16.	1.9	110
534	Platelet reactivity and antiplatelet management in diabetic patients with coronary artery disease. Interventional Cardiology, 2015, 7, 283-293.	0.0	0
535	Platelet reactivity following high loading doses of clopidogrel in patients undergoing primary percutaneous coronary angioplasty: A pilot study. Clinical Trials and Regulatory Science in Cardiology, 2015, 10, 7-12.	1.0	1
536	Platelet Reactivity: Is There a Role to Switch?. Progress in Cardiovascular Diseases, 2015, 58, 278-284.	1.6	4
537	Coronary Revascularization in the Current Era. Progress in Cardiovascular Diseases, 2015, 58, 227-229.	1.6	1
538	Antiplatelet Efficacy of Fixed-Dose Aspirinâ€"Clopidogrel Combination in Patients with Stable Coronary Artery Disease Treated with Drug-Eluting Stent Implantation. Clinical Drug Investigation, 2015, 35, 833-842.	1.1	2
539	Accumetrics-based clopidogrel dosing in endovascular neurosurgery. Neurological Research, 2015, 37, 998-1005.	0.6	10
540	A Bigger Look Into the â€œTherapeutic Windowâ€•of Platelet Reactivity to Adenosine Diphosphate. JACC: Cardiovascular Interventions, 2015, 8, 1988-1989.	1.1	0
541	Antiplatelet drugs and platelet reactivity: is it time to halt clinical research on tailored strategies?. Expert Opinion on Pharmacotherapy, 2015, 16, 449-452.	0.9	8
542	In-hospital switching between adenosine diphosphate receptor inhibitors in patients with acute myocardial infarction treated with percutaneous coronary intervention: Insights into contemporary practice from the TRANSLATE-ACS study. European Heart Journal: Acute Cardiovascular Care, 2015, 4, 499-508.	0.4	68
543	New Approaches to Inhibiting Platelets and Coagulation. Annual Review of Pharmacology and Toxicology, 2015, 55, 373-397.	4.2	44
544	Meta-Analysis Appraising High Maintenance Dose Clopidogrel in Patients Who Underwent Percutaneous Coronary Intervention With and Without High On-Clopidogrel Platelet Reactivity. American Journal of Cardiology, 2015, 115, 592-601.	0.7	8

#	Article	IF	Citations
545	Should Proton Pump Inhibitors Be Withheld From Patients Taking Clopidogrel?. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, 6-7.	0.9	8
546	Prevalence and significance of <scp>CYP</scp>2<scp>C</scp>19*2 and <scp>CYP</scp>2<scp>C</scp>19*17 alleles in a <scp>N</scp>ew <scp>Z</scp>ealand acute coronary syndrome population. Internal Medicine Journal, 2015, 45, 537-545.	0.5	6
547	Recurrent Stroke while on Antiplatelet Therapy. Neurologic Clinics, 2015, 33, 475-489.	0.8	15
548	Pharmacogenomic information in drug labels: European Medicines Agency perspective. Pharmacogenomics Journal, 2015, 15, 201-210.	0.9	110
549	Stent Thrombosis: Current Management and Outcomes. Current Treatment Options in Cardiovascular Medicine, 2015, 17, 365.	0.4	5
550	State-of-the-Art: Hypo-responsiveness to Oral Antiplatelet Therapy in Patients with Type 2 Diabetes Mellitus. Current Cardiovascular Risk Reports, 2015, 9, 4.	0.8	16
551	Under-reporting of venous and arterial thrombotic events in randomized clinical trials: a meta-analysis. Internal and Emergency Medicine, 2015, 10, 219-246.	1.0	11
552	Current antiplatelet agents: place in therapy and role of genetic testing. Journal of Thrombosis and Thrombolysis, 2015, 39, 328-336.	1.0	2
553	Clopidogrel Response Variability: Etiology and Clinical Relevance. Current Cardiovascular Risk Reports, 2015, 9, 1.	0.8	1
554	Novel Anti-platelet Agents in Acute Coronary Syndrome: Mechanisms of Action and Opportunities to Tailor Therapy. Current Atherosclerosis Reports, 2015, 17, 501.	2.0	3
555	Residual platelet reactivity to predict long-term clinical outcomes after clopidogrel loading in patients with acute coronary syndromes: comparison of different cutoff values by light transmission aggregometry from the responsiveness to clopidogrel and stent thrombosis 2-acute coronary syndrome (RECLOSE 2-ACS) study. Journal of Thrombosis and Thrombolysis, 2015, 40, 76-82.	1.0	27
556	High On-Treatment Platelet Reactivity Associated With Prasugrel. Journal of Pharmacy Technology, 2015, 31, 38-42.	0.5	1
557	Clinical Efficacy and Safety of Cilostazol: A Critical Review of the Literature. Drugs, 2015, 75, 377-395.	4.9	52
559	Ticagrelor, prasugrel, or clopidogrel in ST-segment elevation myocardial infarction: which one to choose?. Expert Opinion on Pharmacotherapy, 2015, 16, 1983-1995.	0.9	12
560	Pharmacogenetic-guided algorithms to estimate personalized dose or individual responses to anti-thrombotic drugs. Personalized Medicine Universe, 2015, 4, 13-22.	0.1	0
561	Large early variation of residual platelet reactivity in Acute Coronary Syndrome patients treated with clopidogrel. Thrombosis Research, 2015, 136, 335-340.	0.8	8
562	Optimal cutoff value of P2Y12 reaction units to prevent major adverse cardiovascular events in the acute periprocedural period: Post-hoc analysis of the randomized PRASFIT-ACS study. International Journal of Cardiology, 2015, 182, 541-548.	0.8	49
563	Impact of esomeprazole on platelet reactivity and clinical outcome according to CYP2C19 genotype in coronary heart disease patients during dual antiplatelet therapy. Thrombosis Research, 2015, 135, 1081-1086.	0.8	7

#	Article	IF	Citations
564	Cluster-Randomized Clinical Trial Examining the Impact of Platelet Function Testing on Practice. Circulation: Cardiovascular Interventions, 2015, 8, e001712.	1.4	16
565	More transparency for a therapeutic window in platelet P2Y₁₂inhibition?. European Heart Journal, 2015, 36, 1714-1717.	1.0	5
566	A pharmacodynamic comparison of a personalized strategy for anti-platelet therapy versus ticagrelor in achieving a therapeutic window. International Journal of Cardiology, 2015, 197, 318-325.	0.8	15
567	Review of clopidogrel dose escalation in the current era of potent P2Y12 inhibitors. Expert Review of Clinical Pharmacology, 2015, 8, 411-421.	1.3	4
568	Clopidogrel response variability is associated with endothelial dysfunction in coronary artery disease patients receiving dual antiplatelet therapy. Atherosclerosis, 2015, 242, 102-108.	0.4	20
569	Platelet reactivity assessment with VerifyNowÂ®: Substitute or complement for light transmission aggregometry?. International Journal of Cardiology, 2015, 178, 221-222.	0.8	0
570	The net clinical benefit of personalized antiplatelet therapy in patients undergoing percutaneous coronary intervention. Clinical Science, 2015, 128, 121-130.	1.8	38
571	Platelet function testing in transient ischaemic attack and ischaemic stroke: A comprehensive systematic review of the literature. Platelets, 2015, 26, 402-412.	1.1	44
572	Bleeding and stent thrombosis on P2Y₁₂-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. European Heart Journal, 2015, 36, 1762-1771.	1.0	297
573	Impact of tailored anti-P2Y12 therapies in acute coronary syndromes. Pharmacogenomics, 2015, 16, 493-499.	0.6	4
574	CYP2C19*2 genotype influence in acute coronary syndrome patients undergoing serial clopidogrel dose tailoring based on platelet function testing: Analysis from randomized controlled trial NCT02096419. International Journal of Cardiology, 2015, 186, 282-285.	0.8	6
575	Predictive Value of High Residual Platelet Reactivity by Flow Cytometry for Outcomes of Ischemic Stroke Patients on Clopidogrel Therapy. Journal of Stroke and Cerebrovascular Diseases, 2015, 24, 1145-1152.	0.7	10
576	Correlation Between SNPs in Candidate Genes and VerifyNow-Detected Platelet Responsiveness to Aspirin and Clopidogrel Treatment. Cardiovascular Drugs and Therapy, 2015, 29, 137-146.	1.3	10
577	Is a high maintenance dose of clopidogrel suitable for overcoming clopidogrel resistance in patients?. International Journal of Clinical Pharmacy, 2015, 37, 758-761.	1.0	6
578	Impact of cytochrome P450 2C19*2 polymorphism on intra-stent thrombus assessed by follow-up optical coherence tomography in Chinese patients receiving clopidogrel. Journal of Thrombosis and Thrombolysis, 2015, 40, 88-96.	1.0	4
579	P2Y12receptor inhibitors for secondary prevention of ischemic stroke. Expert Opinion on Pharmacotherapy, 2015, 16, 1149-1165.	0.9	12
580	Determinants of subacute response to clopidogrel: relative impact of CYP2C19 genotype and PGE1/adenylate cyclase signalling. Thrombosis Research, 2015, 136, 308-314.	0.8	8
581	Switching from Clopidogrel to Prasugrel in patients undergoing PCI: A meta-analytic overview. Platelets, 2016, 27, 1-12.	1.1	5

#	Article	IF	Citations
582	Genetically Determined Platelet Reactivity and Related Clinical Implications. High Blood Pressure and Cardiovascular Prevention, 2015, 22, 257-264.	1.0	5
583	Prasugrel hydrochloride for the treatment of acute coronary syndromes. Expert Opinion on Pharmacotherapy, 2015, 16, 585-596.	0.9	4
584	Genotype-based clinical trials in cardiovascular disease. Nature Reviews Cardiology, 2015, 12, 475-487.	6.1	37
585	Dual antiplatelet therapy tailored on platelet function test after coronary stent implantation: a real-world experience. Internal and Emergency Medicine, 2015, 10, 805-814.	1.0	6
586	Anesthesia for Interventional Neuroradiology. International Anesthesiology Clinics, 2015, 53, 87-106.	0.3	12
587	Does the response to aspirin and clopidogrel vary over 6Âmonths in patients with ischemic heart disease?. Journal of Thrombosis and Haemostasis, 2015, 13, 920-930.	1.9	7
588	Meta-Analysis of Direct and Indirect Comparison of Ticagrelor and Prasugrel Effects on Platelet Reactivity. American Journal of Cardiology, 2015, 115, 716-723.	0.7	30
589	Prevention and treatment of atherosclerosis in haemophilia â€“ how to balance risk of bleeding with risk of ischaemic events. European Journal of Haematology, 2015, 94, 23-29.	1.1	11
590	Pharmacology of antithrombotic drugs: an assessment of oral antiplatelet and anticoagulant treatments. Lancet, The, 2015, 386, 281-291.	6.3	209
591	Clinical evidence for oral antiplatelet therapy in acute coronary syndromes. Lancet, The, 2015, 386, 292-302.	6.3	59
592	Current State and Novel Approaches of Antiplatelet Therapy. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 1327-1338.	1.1	62
593	Prasugrel in Clopidogrel Nonresponders Undergoing Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2015, 8, 1563-1570.	1.1	23
594	Stent thrombosis and restenosis: what have we learned and where are we going? The Andreas GrÃ¼ntzig Lecture ESC 2014. European Heart Journal, 2015, 36, 3320-3331.	1.0	441
595	Fixed and Modifiable Correlates of Drug-Eluting Stent Thrombosis From a Large All-Comers Registry. Circulation: Cardiovascular Interventions, 2015, 8, .	1.4	13
596	Routine genotyping of patients on clopidogrel: Why the resistance?. Indian Heart Journal, 2015, 67, 93-94.	0.2	0
597	Optimal- vs. standard-antiplatelet therapy on platelet function and long-term clinical outcomes in patients with high on-treatment platelet reactivity: 2-year outcomes of the multicentre, randomized Optimal-antiPlatelet Therapy (OPT) trial. European Heart Journal Supplements, 2015, 17, B23-B31.	0.0	4
598	Revisiting the Clopidogrelâ€“Proton Pump Inhibitor Interaction. Circulation: Cardiovascular Interventions, 2015, 8, .	1.4	3
599	Prasugrel in Clopidogrel Nonresponders. JACC: Cardiovascular Interventions, 2015, 8, 1571-1573.	1.1	1

#	Article	IF	Citations
600	Dual antiplatelet therapy: optimal timing, management, and duration. European Heart Journal - Cardiovascular Pharmacotherapy, 2015, 1, 198-204.	1.4	32
601	Design and rationale of TROCADERO: A TRial Of Caffeine to Alleviate DyspnEa Related to ticagrelOr. American Heart Journal, 2015, 170, 465-470.	1.2	11
602	Genetic and platelet function testing of antiplatelet therapy for percutaneous coronary intervention: the ARCTIC-GENE study. European Journal of Clinical Pharmacology, 2015, 71, 1315-1324.	0.8	31
603	Antiplatelet therapy in acute coronary syndromes. Expert Opinion on Pharmacotherapy, 2015, 16, 2133-2147.	0.9	30
604	Duration of Dual Anti-Platelet Therapy Post-Percutaneous Intervention: Is There A Correct Amount of Time?. Progress in Cardiovascular Diseases, 2015, 58, 285-298.	1.6	6
605	Independent Predictors of Major Adverse Events following Coronary Stenting over 28 Months of Follow-Up. Cardiology, 2015, 132, 176-181.	0.6	10
606	Platelet Testing is Associated with Worse Clinical Outcomes for Patients Treated with the Pipeline Embolization Device. American Journal of Neuroradiology, 2015, 36, 2090-2095.	1.2	42
607	Changes in platelet function independent of pharmacotherapy following coronary intervention in non-ST-elevation myocardial infarction patients. Atherosclerosis, 2015, 243, 320-327.	0.4	2
608	Comparing prasugrel to twice daily clopidogrel post percutaneous coronary intervention in a Veterans Affairs population. American Journal of Health-System Pharmacy, 2015, 72, S98-S103.	0.5	3
609	Evaluation of platelet response to different clopidogrel dosing regimens in patients with acute coronary syndrome in clinical practice. Platelets, 2015, 26, 127-131.	1.1	2
610	Association between platelet reactivity and circulating platelet-derived microvesicles in patients with acute coronary syndrome. Platelets, 2015, 26, 467-473.	1.1	25
611	Clopidogrel: A multifaceted affair. Journal of Clinical Pharmacology, 2015, 55, 1-9.	1.0	7
612	Tailored antiplatelet therapy to improve prognosis in patients exhibiting clopidogrel low-response prior to percutaneous coronary intervention for stable angina or non-ST elevation acute coronary syndrome. Platelets, 2015, 26, 521-529.	1.1	13
613	A systematic review and critical assessment of 11 discordant meta-analyses on reduced-function CYP2C19 genotype and risk of adverse clinical outcomes in clopidogrel users. Genetics in Medicine, 2015, 17, 3-11.	1.1	40
615	Novel antiplatelet agents in acute coronary syndrome. Nature Reviews Cardiology, 2015, 12, 30-47.	6.1	299
616	Evaluation of the INNOVANCE PFA P2Y assay and its association withCYP2C19genotypes. Platelets, 2015, 26, 148-153.	1.1	4
617	Efficacy and safety of cilostazol based triple antiplatelet treatment versus dual antiplatelet treatment in patients undergoing coronary stent implantation: an updated meta-analysis of the randomized controlled trials. Journal of Thrombosis and Thrombolysis, 2015, 39, 23-34.	1.0	25
618	Lack of association between peri-procedural myocardial damage and CYP2C19 gene variant in elective percutaneous coronary intervention. Heart and Vessels, 2015, 30, 572-579.	0.5	1

#	Article	IF	Citations
619	Intensified Antiplatelet Treatment Reduces Major Cardiac Events in Patients with Clopidogrel Low Response. Chinese Medical Journal, 2016, 129, 984-991.	0.9	7
620	Switching of Ticagrelor to Clopidogrel at 3 Months in Patients Treated for Acute Care Syndrome; Single Centre Experience. Cardiovascular Pharmacology: Open Access, 2016, 5, .	0.1	6
621	Is Dual Antiplatelet Therapy Necessary in Transcatheter Aortic Valve Implantation?. International Heart Journal, 2016, 57, 129-131.	0.5	0
622	Type 2 Diabetes and ADP Receptor Blocker Therapy. Journal of Diabetes Research, 2016, 2016, 1-7.	1.0	8
623	The Ratio of ADP- to TRAP-Induced Platelet Aggregation Quantifies P2Y12-Dependent Platelet Inhibition Independently of the Platelet Count. PLoS ONE, 2016, 11, e0149053.	1.1	7
624	Vascular risk levels affect the predictive value of platelet reactivity for the occurrence of MACE in patients on clopidogrel. Thrombosis and Haemostasis, 2016, 115, 823-825.	1.8	32
625	Impact of timing from blood sampling to pharmacodynamic assessment on measures of platelet reactivity in patients treated with P2Y12 receptor inhibitors. Thrombosis and Haemostasis, 2016, 116, 1060-1069.	1.8	8
626	Clopidgrel Resistance and Periprocedual Thromboembolic Complications in Neuroendovascular Treatment. Journal of Neuroendovascular Therapy, 2016, 10, 19-24.	0.1	0
627	Which platelet function test best reflects the in vivo plasma concentrations of ticagrelor and its active metabolite?. Thrombosis and Haemostasis, 2016, 116, 1140-1149.	1.8	10
628	Comparative Efficacy and Safety of Prasugrel, Ticagrelor, and Standard-Dose and High-Dose Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention. American Journal of Therapeutics, 2016, 23, e52-e62.	0.5	11
629	Antiplatelet and Anticoagulation Treatment in Patients With Nonâ€“ST-Segment Elevation Acute Coronary Syndrome. Cardiology in Review, 2016, 24, 170-176.	0.6	2
630	Are Immature Platelets Growing Up?. Journal of the American College of Cardiology, 2016, 68, 294-296.	1.2	7
631	Measurement of residual platelet thrombogenicity under arterial shear conditions in cerebrovascular disease patients receiving antiplatelet therapy. Journal of Thrombosis and Haemostasis, 2016, 14, 1788-1797.	1.9	15
632	Ticagrelor. Blood Coagulation and Fibrinolysis, 2016, 27, 117-120.	0.5	13
633	Clinical significance of residual platelet reactivity in patients treated with platelet P2Y12 inhibitors. Vascular Pharmacology, 2016, 84, 25-27.	1.0	18
634	Safety and efficacy of policosanol in patients with high onâ€treatment platelet reactivity after drugâ€eluting stent implantation: twoâ€year followâ€up results. Cardiovascular Therapeutics, 2016, 34, 337-342.	1.1	11
635	Physician response to implementation of genotypeâ€tailored antiplatelet therapy. Clinical Pharmacology and Therapeutics, 2016, 100, 67-74.	2.3	47
636	The place of viscoelastic testing in clinical practice. British Journal of Haematology, 2016, 173, 37-48.	1.2	83

#	Article	IF	Citations
637	State of the art: Oral antiplatelet therapy. JRSM Cardiovascular Disease, 2016, 5, 204800401665251.	0.4	6
641	High platelet reactivity affects the clinical outcomes of patients undergoing percutaneous coronary intervention. BMC Cardiovascular Disorders, 2016, 16, 240.	0.7	15
642	High residual platelet reactivity - Does the problem persist even with new antiplatelet drugs?. Cor Et Vasa, 2016, 58, e631-e635.	0.1	1
643	Comparison of Three Tests to Distinguish Platelet Reactivity in Patients with Renal Impairment during Dual Antiplatelet Therapy. Nephron, 2016, 132, 191-197.	0.9	9
644	Bleeding events and maintenance dose of prasugrel: BLESS pilot study. Open Heart, 2016, 3, e000460.	0.9	8
645	Switching from clopidogrel to prasugrel or ticagrelor: tips and tricks. European Heart Journal, 2016, 37, 2731-2733.	1.0	2
646	Pharmacodynamic evaluation of clopidogrel reloading vs. switching to prasugrel or ticagrelor in clopidogrel resistant Indian patients. Clinical Trials and Regulatory Science in Cardiology, 2016, 13, 14-20.	1.0	0
647	Point-of-Care Technologies for Precision Cardiovascular Care and Clinical Research. JACC Basic To Translational Science, 2016, 1, 73-86.	1.9	42
648	Platelet function testing after acute myocardial infarction: The correlation among various assays is insufficient. Cor Et Vasa, 2016, 58, e411-e418.	0.1	0
649	Optimal P2Y 12 Inhibitor in Patients WithÂST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2016, 9, 1036-1046.	1.1	42
650	Simultaneous subacute coronary artery stent thrombosis in a carrier of two CYP2C19 lossâ€“of function polymorphisms (*2/*3). International Journal of Cardiology, 2016, 212, 148-150.	0.8	5
651	Validation of a P2Y₁₂-receptor specific whole blood platelet aggregation assay. Platelets, 2016, 27, 668-672.	1.1	6
652	Impact of Anemia on Platelet Reactivity and Ischemic and Bleeding Risk: From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Study. American Journal of Cardiology, 2016, 117, 1877-1883.	0.7	34
653	Platelet-Mediated Thrombosis. Circulation Research, 2016, 118, 1380-1391.	2.0	56
654	Predictive performance of adding platelet reactivity on top of CRUSADE score for 1-year bleeding risk in patients with acute coronary syndrome. Journal of Thrombosis and Thrombolysis, 2016, 42, 360-368.	1.0	10
655	Effect of Modifying Antiplatelet Treatment to Ticagrelor in High-Risk Coronary Patients With Low Response to Clopidogrel (MATTIS). Canadian Journal of Cardiology, 2016, 32, 1246.e13-1246.e19.	0.8	4
656	Optimal Antiplatelet Therapy in ST-Segment Elevation Myocardial Infarction. Interventional Cardiology Clinics, 2016, 5, 481-495.	0.2	1
657	CYP2C19 genotyping combined with on-clopidogrel platelet reactivity in predicting major adverse cardiovascular events in Chinese patients with percutaneous coronary intervention. Thrombosis Research, 2016, 147, 108-114.	0.8	10

#	Article	IF	Citations
659	Thienopyridine reloading in clopidogrel-loaded patients undergoing percutaneous coronary interventions: The PRAISE study. International Journal of Cardiology, 2016, 222, 639-644.	0.8	4
660	Antithrombotic Approaches in Acute Coronary Syndromes: Optimizing Benefit vs Bleeding Risks. Mayo Clinic Proceedings, 2016, 91, 1413-1447.	1.4	10
661	What have we learned from the ANTARCTIC trial?. Nature Reviews Cardiology, 2016, 13, 639-640.	6.1	4
662	Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial. Lancet, The, 2016, 388, 2015-2022.	6.3	303
663	Smoking and Clopidogrel Response Revisited. JACC: Cardiovascular Interventions, 2016, 9, 1691-1693.	1.1	9
664	Improved predictive value of GRACE risk score combined with platelet reactivity for 1-year cardiovascular risk in patients with acute coronary syndrome who underwent coronary stent implantation. Platelets, 2016, 27, 650-657.	1.1	7
665	Platelet function testing as a biomarker for efficacy of antiplatelet drugs. Biomarkers in Medicine, 2016, 10, 903-918.	0.6	8
666	Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2016, 9, .	1.4	83
667	Diabetes mellitus, CYP2C19 genotype, and response to escalating doses of clopidogrel. Thrombosis and Haemostasis, 2016, 116, 69-77.	1.8	19
668	Platelet aggregation and risk of stent thrombosis or bleeding in interventionally treated diabetic patients with acute coronary syndrome. BMC Cardiovascular Disorders, 2016, 16, 252.	0.7	9
669	Association of VEGFR-2 Gene Polymorphisms With Clopidogrel Resistance in Patients With Coronary Heart Disease. American Journal of Therapeutics, 2016, 23, e1663-e1670.	0.5	9
670	Oral P2Y₁₂ Receptor Inhibitors in Hemodialysis Patients Undergoing Percutaneous Coronary Interventions: CurrentÂKnowledge and Future Directions. Seminars in Dialysis, 2016, 29, 374-381.	0.7	7
671	High On-Treatment Platelet Reactivity in Peripheral Arterial Disease: A Pilot Study to Find the Optimal Test and Cut Off Values. European Journal of Vascular and Endovascular Surgery, 2016, 52, 198-204.	0.8	24
672	Impact of an integrated treatment algorithm based on platelet function testing and clinical risk assessment: results of the TRIAGE Patients Undergoing Percutaneous Coronary Interventions To Improve Clinical Outcomes Through Optimal Platelet Inhibition study. Journal of Thrombosis and Thrombolysis, 2016, 42, 186-196.	1.0	3
673	Carotid Endarterectomy on Antiplatelet Agents in the Era of Point-of-Care Testing. World Neurosurgery, 2016, 93, 215-220.	0.7	4
674	Developments in Oral Antiplatelet Agents for the Treatment of Acute Coronary Syndromes. Journal of Pharmacy Practice, 2016, 29, 239-249.	0.5	10
675	The challenge for predicting bleeding events by assessing platelet reactivity following coronary stenting. International Journal of Cardiology, 2016, 207, 128-131.	0.8	7
676	Clopidogrel Response Variability. Journal of Pharmacy Practice, 2016, 29, 26-34.	0.5	24

#	Article	IF	Citations
677	Advanced age and highâ€residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor. Journal of Thrombosis and Haemostasis, 2016, 14, 57-64.	1.9	57
678	Antiplatelet Therapy in Percutaneous Coronary Intervention. Interventional Cardiology Clinics, 2016, 5, 221-237.	0.2	5
679	Clinical Significance of Laboratory-determined Aspirin Poor Responsiveness After Primary Percutaneous Coronary Intervention. Cardiovascular Drugs and Therapy, 2016, 30, 151-158.	1.3	4
680	Effect of CYP2C19 Polymorphisms on the Platelet Response to Clopidogrel and Influence on the Effect of High Versus Standard Dose Clopidogrel in Carotid Artery Stenting. European Journal of Vascular and Endovascular Surgery, 2016, 51, 175-186.	0.8	22
681	Reply. JACC: Cardiovascular Interventions, 2016, 9, 106-107.	1.1	0
682	Combination of P2Y12 reaction unit and percentage of platelet inhibition assessed by VerifyNow P2Y12 assay is a useful predictor of long-term clinical outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Thrombosis Research, 2016, 139, 114-120.	0.8	11
683	Blood-Derived Extracellular RNA and Platelet Pathobiology. Circulation Research, 2016, 118, 374-376.	2.0	7
685	The use of platelet reactivity testing in patients on antiplatelet therapy for prediction of bleeding events after cardiac surgery. Vascular Pharmacology, 2016, 77, 19-27.	1.0	15
686	Platelet reactivity after administration of third generation P2Y12-antagonists does not depend on body weight in contrast to clopidogrel. Journal of Thrombosis and Thrombolysis, 2016, 42, 84-89.	1.0	6
687	Evaluation of the F2R IVS-14A/T PAR1 polymorphism with subsequent cardiovascular events and bleeding in patients who have undergone percutaneous coronary intervention. Journal of Thrombosis and Thrombolysis, 2016, 41, 656-662.	1.0	7
688	Platelet reactivity in MitraClip patients. Vascular Pharmacology, 2016, 77, 54-59.	1.0	14
689	Predictors of high on-clopidogrel platelet reactivity in patients with acute coronary syndrome. Platelets, 2016, 27, 159-167.	1.1	9
690	Switching from prasugrel to clopidogrel based on Cytochrome P450 2C19 genotyping in East Asian patients stabilized after acute myocardial infarction. Platelets, 2016, 27, 301-307.	1.1	7
691	Update on oral antithrombotic therapy for secondary prevention following non-ST segment elevation myocardial infarction. Trends in Cardiovascular Medicine, 2016, 26, 321-334.	2.3	3
692	On-treatment platelet reactivity: State of the art and perspectives. Vascular Pharmacology, 2016, 77, 8-18.	1.0	19
693	2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. European Heart Journal, 2016, 37, 267-315.	1.0	5,890
694	Immature platelet fraction and high-on treatment platelet reactivity with ticagrelor in patients with acute coronary syndromes. Journal of Thrombosis and Thrombolysis, 2016, 41, 663-670.	1.0	21
695	Personalized ADP-receptor inhibition strategy and outcomes following primary PCI for STEMI (PASTOR) Tj ETQq1 1 0.784314 rgBT /Ov	0.8	4

#	Article	IF	Citations
696	Switching P2Y12-receptor inhibitors in patients with coronary artery disease. Nature Reviews Cardiology, 2016, 13, 11-27.	6.1	154
697	Platelet function testing: does a randomized controlled trial settle the debate?. Journal of NeuroInterventional Surgery, 2016, 8, 768-769.	2.0	3
698	Optimal timing of initiation of oral P2Y12-receptor antagonist therapy in patients with non-ST elevation acute coronary syndromes. Lessons learnt from the ACCOAST-trial. European Heart Journal: Acute Cardiovascular Care, 2016, 5, 282-288.	0.4	3
699	Traditional clinical risk factors predict clopidogrel hypo-responsiveness in unselected patients undergoing non-emergent percutaneous coronary intervention. Platelets, 2016, 27, 51-58.	1.1	2
700	A prospective randomized evaluation of a pharmacogenomic approach to antiplatelet therapy among patients with ST-elevation myocardial infarction: the RAPID STEMI study. Pharmacogenomics Journal, 2016, 16, 71-78.	0.9	35
701	Association of thrombelastographic parameters with post-stenting ischemic events. Journal of NeuroInterventional Surgery, 2017, 9, 192-195.	2.0	22
702	Influence of smoking on the antiplatelet effect of clopidogrel differs according to clopidogrel dose: Insights from the GRAVITAS trial. Catheterization and Cardiovascular Interventions, 2017, 89, 190-198.	0.7	18
703	Clinical significance of platelet reactivity during prasugrel therapy in patients with acute myocardial infarction. Journal of Cardiology, 2017, 70, 35-40.	0.8	4
704	Contribution of whole platelet aggregometry to the endovascular management of unruptured aneurysms: an institutional experience. Journal of NeuroInterventional Surgery, 2017, 9, 974-977.	2.0	5
706	Comparison of Multiplate and VerifyNow platelet function tests in predicting clinical outcome in patients with acute coronary syndromes. Thrombosis Research, 2017, 152, 14-19.	0.8	21
708	Oral antiplatelet drugs in patients with chronic kidney disease (CKD): a review. Journal of Thrombosis and Thrombolysis, 2017, 43, 519-527.	1.0	10
709	Sex Differences in the Clinical Impact of High Platelet Reactivity After Percutaneous Coronary Intervention With Drug-Eluting Stents. Circulation: Cardiovascular Interventions, 2017, 10, .	1.4	27
710	Conundrums of Platelet Function Testing. Circulation: Cardiovascular Interventions, 2017, 10, .	1.4	0
711	Comparison of Platelet Reactivity in Black Versus White Patients With Acute Coronary Syndromes After Treatment With Ticagrelor. American Journal of Cardiology, 2017, 119, 1135-1140.	0.7	5
712	Pharmacogenetics in cardiovascular diseases: State of the art and implementation-recommendations of the French National Network of Pharmacogenetics (RNPGx). Therapie, 2017, 72, 257-267.	0.6	25
713	Optimal Same-Day Platelet Inhibition in Patients Receiving Drug-Eluting Stents With or Without Previous Maintenance Thienopyridine Therapy : from the Evaluation of Platelet Inhibition in Patients Having A VerifyNow Assay (EPIPHANY) Trial. American Journal of Cardiology, 2017, 119, 991-995.	0.7	4
714	Optimal duration of dual antiplatelet therapy after acute coronary syndromes and coronary stenting. Heart, 2017, 103, 871-884.	1.2	4
715	Single or dual antiplatelet therapy after PCI. Nature Reviews Cardiology, 2017, 14, 294-303.	6.1	35

#	Article	IF	Citations
716	Duration of dual antiplatelet therapy in acute coronary syndrome. Heart, 2017, 103, 573-580.	1.2	34
717	The association between high on-treatment platelet reactivity and early recurrence of ischemic events after minor stroke or TIA. Neurological Research, 2017, 39, 719-726.	0.6	17
718	Pharmacogenomics of Antiplatelet Drugs. , 2017, , 1325-1340.		0
719	Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors. European Heart Journal - Cardiovascular Pharmacotherapy, 2017, 3, 221-234.	1.4	43
720	Use of Platelet Function Testing Before Pipeline Embolization Device Placement. Stroke, 2017, 48, 1322-1330.	1.0	109
721	Antiplatelet treatments. Current Opinion in Cardiology, 2017, 32, 356-362.	0.8	4
722	Is arachidonic acid stimulation really a test for the response to aspirin? Time to think again?. Expert Review of Cardiovascular Therapy, 2017, 15, 35-46.	0.6	11
723	Current Role of Platelet Function Testing in Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting. Interventional Cardiology Clinics, 2017, 6, 151-166.	0.2	4
724	Individualized dual antiplatelet therapy based on platelet function testing in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials. BMC Cardiovascular Disorders, 2017, 17, 157.	0.7	17
725	Platelet testing in flow diversion: a review of the evidence. Neurosurgical Focus, 2017, 42, E5.	1.0	34
726	The genetic basis of antiplatelet and anticoagulant therapy: A pharmacogenetic review of newer antiplatelets (clopidogrel, prasugrel and ticagrelor) and anticoagulants (dabigatran, rivaroxaban,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 3	1.6	28
727	Impact of mean platelet aggregation degree on long-term clinical outcomes among patients undergoing a complex percutaneous coronary intervention. Coronary Artery Disease, 2017, 28, 478-485.	0.3	3
728	Use of platelet function testing to guide the timing of coronary artery bypass surgery. Coronary Artery Disease, 2017, 28, 454-456.	0.3	0
729	How I use laboratory monitoring of antiplatelet therapy. Blood, 2017, 130, 713-721.	0.6	42
730	Clinical and educational impact of pharmacogenomics testing: a case series from the INGENIOUS trial. Pharmacogenomics, 2017, 18, 835-841.	0.6	6
731	Reply. JACC: Cardiovascular Interventions, 2017, 10, 105-106.	1.1	0
732	Point-of-Care Testing in Neurosurgery. Seminars in Thrombosis and Hemostasis, 2017, 43, 416-422.	1.5	8
733	Platelet Reactivity and Clinical Outcomes After Coronary Artery Implantation of Drug-Eluting Stents in Subjects With Peripheral Arterial Disease. Circulation: Cardiovascular Interventions, 2017, 10, .	1.4	14

#	Article	IF	Citations
734	Tailoring of medical treatment: hemostasis and thrombosis towards precision medicine. Haematologica, 2017, 102, 411-418.	1.7	14
735	Does percutaneous coronary stent implantation increase platelet reactivity?. Blood Reviews, 2017, 31, 271-275.	2.8	5
736	Association of measured platelet reactivity with changes in P2Y 12 receptor inhibitor therapy and outcomes after myocardial infarction: Insights into routine clinical practice from the TReatment with ADP receptor iNhibitorS: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) study. American Heart Journal, 2017, 187, 19-28.	1.2	14
737	Clinical Impact of Pharmacogenomics of Clopidogrel in Stroke. Circulation, 2017, 135, 34-37.	1.6	13
738	Assessing strategies to improve patient management. Nature Reviews Cardiology, 2017, 14, 77-78.	6.1	2
739	Novel strategies for assessing platelet reactivity. Future Cardiology, 2017, 13, 33-47.	0.5	18
740	International Expert Consensus on Switching Platelet P2Y ₁₂ Receptorâ€“Inhibiting Therapies. Circulation, 2017, 136, 1955-1975.	1.6	293
741	Antiplatelet Agents for the Treatment and Prevention of Coronary Atherothrombosis. Journal of the American College of Cardiology, 2017, 70, 1760-1776.	1.2	140
742	Review of aspirin and clopidogrel resistance in peripheral arterial disease. Journal of Vascular Surgery, 2017, 66, 1576-1586.	0.6	63
743	Dual antiplatelet therapy guided by platelet function testing. Lancet, The, 2017, 390, 1718-1720.	6.3	39
744	Total Thrombusâ€formation Analysis System Predicts Periprocedural Bleeding Events in Patients With Coronary Artery Disease Undergoing Percutaneous Coronary Intervention. Journal of the American Heart Association, 2017, 6, .	1.6	24
745	Effects of ticagrelor versus clopidogrel on platelet function in fibrinolytic-treated STEMI patients undergoing early PCI. American Heart Journal, 2017, 192, 105-112.	1.2	35
746	ANTARCTIC: platelet function testing to adjust therapy â€“ Authors' reply. Lancet, The, 2017, 389, 1193-1194.	6.3	2
747	Association ofCYP2C19*2polymorphism with clopidogrel response and 1-year major adverse cardiovascular events in a multiethnic population with drug-eluting stents. Pharmacogenomics, 2017, 18, 1225-1239.	0.6	5
748	Platelet aggregation and the risk of stent thrombosis or bleeding in elective percutaneous coronary intervention patients. Blood Coagulation and Fibrinolysis, 2017, 28, 383-388.	0.5	1
749	Update on antithrombotic therapy after percutaneous coronary revascularisation. Lancet, The, 2017, 390, 810-820.	6.3	25
750	Platelet Reactivity. JACC: Cardiovascular Interventions, 2017, 10, 1618-1620.	1.1	1
752	Time course of the antiplatelet effect after switching to clopidogrel from initial prasugrel therapy in patients with acute coronary syndrome. Heart and Vessels, 2017, 32, 1432-1438.	0.5	2

#	Article	IF	Citations
753	Platelets redox balance assessment: Current evidence and methodological considerations. Vascular Pharmacology, 2017, 93-95, 6-13.	1.0	23
754	Clinical determinants of clopidogrel responsiveness in a heterogeneous cohort of Puerto Rican Hispanics. Therapeutic Advances in Cardiovascular Disease, 2017, 11, 235-241.	1.0	7
755	PEAR1 is not a major susceptibility gene for cardiovascular disease in a Flemish population. BMC Medical Genetics, 2017, 18, 45.	2.1	13
756	P2Y12 receptor inhibitor resistance and coronary artery disease. Current Opinion in Cardiology, 2017, 32, 617-626.	0.8	1
757	Identifying clinically relevant sources of variability: The clopidogrel challenge. Clinical Pharmacology and Therapeutics, 2017, 101, 264-273.	2.3	14
758	Cell-derived microvesicles in cardiovascular diseases and antiplatelet therapy monitoring â€" A lesson for future trials? Current evidence, recent progresses and perspectives of clinical application. International Journal of Cardiology, 2017, 226, 93-102.	0.8	20
759	The effect of P2Y12 inhibition on platelet activation assessed with aggregation- and flow cytometry-based assays. Platelets, 2017, 28, 567-575.	1.1	9
760	Benefit of Switching Dual Antiplatelet Therapy After Acute Coronary Syndrome According to On-Treatment Platelet Reactivity. JACC: Cardiovascular Interventions, 2017, 10, 2560-2570.	1.1	36
761	A randomised trial on platelet function-guided de-escalation of antiplatelet treatment in ACS patients undergoing PCI. Thrombosis and Haemostasis, 2017, 117, 188-195.	1.8	36
762	Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial. Lancet, The, 2017, 390, 1747-1757.	6.3	443
763	Tailored antiplatelet therapy in high-risk ACS patients treated with PCI stenting: lessons from the ANTARCTIC trial. Journal of Thoracic Disease, 2017, 9, E440-E443.	0.6	2
764	Decreased platelet responsiveness to clopidogrel correlates with CYP2C19 and PON1 polymorphisms in atherosclerotic patients. Brazilian Journal of Medical and Biological Research, 2017, 50, e5660.	0.7	13
765	Clinical outcomes in patients treated for coronary in-stent restenosis with drug-eluting balloons: Impact of high platelet reactivity. PLoS ONE, 2017, 12, e0188493.	1.1	4
766	Administration of Ticagrelor and Double-Dose Clopidogrel Based on Platelet Reactivity Determined by VerifyNow-P2Y12 for Chinese Subjects After Elective PCI. International Heart Journal, 2017, 58, 167-173.	0.5	3
767	Safety and Efficacy of Prasugrel with Endovascular Treatment for Unruptured Cerebral Aneurysm. Journal of Neuroendovascular Therapy, 2017, 11, 553-557.	0.1	6
768	Platelet function testing: dead or alive. Journal of Thrombosis and Haemostasis, 2018, 16, 984-986.	1.9	23
769	Antiplatelet Therapy Changes for Patients With Myocardial Infarction With Recurrent Ischemic Events: Insights Into Contemporary Practice From the TRANSLATEâ€ACS (Treatment With ADP Receptor) Tj ETQq0 0 0 rgBT /Overlock 1	1.6	2
770	ADP Platelet Hyperreactivity Predicts Cardiovascular Disease in the FHS (Framingham Heart Study). Journal of the American Heart Association, 2018, 7, .	1.6	51

#	Article	IF	Citations
771	Detection of individual responses to clopidogrel: Validation of a novel, rapid analysis using thrombelastography 6s. Cardiovascular Therapeutics, 2018, 36, e12433.	1.1	12
772	Restenosis, Stent Thrombosis, and Bleeding Complications. Journal of the American College of Cardiology, 2018, 71, 1676-1695.	1.2	134
773	Impact of platelet reactivity on 5-year clinical outcomes following percutaneous coronary intervention: a landmark analysis. Journal of Thrombosis and Thrombolysis, 2018, 45, 496-503.	1.0	11
774	Randomized Comparisons of Double-Dose Clopidogrel or Adjunctive Cilostazol Versus Standard Dual Antiplatelet in Patients With High Posttreatment Platelet Reactivity. Circulation, 2018, 137, 2231-2245.	1.6	68
775	Body Mass Index and Plasma P-Selectin before Coronary Stenting Predict High Residual Platelet Reactivity at 6 Months on Dual Antiplatelet Therapy. Cardiology, 2018, 139, 132-136.	0.6	8
776	Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end pointsâ€"Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC). American Heart Journal, 2018, 198, 152-159.	1.2	24
777	The Evolving Face of Myocardial Reperfusion in Acute Coronary Syndromes: A Primer for the Internist. Mayo Clinic Proceedings, 2018, 93, 199-216.	1.4	1
778	Case-based implementation of the 2017 ESC Focused Update on Dual Antiplatelet Therapy in Coronary Artery Disease. European Heart Journal, 2018, 39, e1-e33.	1.0	22
779	Antithrombotic and Antiplatelet Therapy. , 2018, , 53-59.		0
780	Pharmacogenomic Testing to Select Antiplatelet Therapy. Journal of the American College of Cardiology, 2018, 71, 1878-1881.	1.2	6
781	Antiplatelet Therapy in ACS Patients: Comparing Appropriate P2Y12 Inhibition by Clopidogrel to the Use of New P2Y12 Inhibitors. Journal of Atherosclerosis and Thrombosis, 2018, 25, 674-689.	0.9	3
782	Temporal Changes in Platelet Response in Acute Coronary Syndrome Patients With Prasugrel and Clopidogrel After Stent Implantation. Circulation Journal, 2018, 82, 353-360.	0.7	5
783	Emerging Role of Precision Medicine in Cardiovascular Disease. Circulation Research, 2018, 122, 1302-1315.	2.0	218
784	Optimal platelet function test for in-stent tissue protrusion following carotid artery stenting. Journal of International Medical Research, 2018, 46, 1866-1875.	0.4	2
785	Dual Antiplatelet Therapy Guided by <i>CYP2C19</i> Polymorphisms after Implantation of Second-Generation Drug-Eluting Stents for Management of Acute Coronary Syndrome. International Heart Journal, 2018, 59, 21-26.	0.5	12
786	Pharmacogenomic Approach to SelectingÂAntiplatelet Therapy in PatientsÂWith Acute Coronary Syndromes. Journal of the American College of Cardiology, 2018, 71, 1869-1877.	1.2	148
787	Aggregometry in the settings of thrombocytopenia, thrombocytosis and antiplatelet therapy. Platelets, 2018, 29, 644-649.	1.1	9
788	Potentiation of thrombus instability: a contributory mechanism to the effectiveness of antithrombotic medications. Journal of Thrombosis and Thrombolysis, 2018, 45, 593-602.	1.0	6

#	Article	IF	Citations
789	Preliminary Study of Tirofiban Infusion in Coil Embolization of Ruptured Intracranial Aneurysms. Neurosurgery, 2018, 82, 76-84.	0.6	22
790	Antiplatelet and Anticoagulant Drugs. , 2018, , 303-320.		1
791	Personalizing antiplatelet therapies: What have we learned from recent trials?. Platelets, 2018, 29, 131-139.	1.1	8
792	Sepsis favors high-on-clopidogrel platelet reactivity. Platelets, 2018, 29, 76-78.	1.1	8
793	Role of genetic testing in patients undergoing percutaneous coronary intervention. Expert Review of Clinical Pharmacology, 2018, 11, 151-164.	1.3	57
794	2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. European Heart Journal, 2018, 39, 213-260.	1.0	2,246
795	2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. European Journal of Cardio-thoracic Surgery, 2018, 53, 34-78.	0.6	261
796	CYP2C19 Genotyping in Percutaneous Coronary Intervention-TreatedÂPatients. JACC: Cardiovascular Interventions, 2018, 11, 192-194.	1.1	3
797	Switch to Ticagrelor in critical limb ischemia antiplatelet study (STT-CLIPS). Cardiovascular Revascularization Medicine, 2018, 19, 319-323.	0.3	4
799	Impact of Test Conditions on ADP-Induced Platelet Function Results With the Multiplate Assay: Is Further Standardization Required?. Journal of Cardiovascular Pharmacology and Therapeutics, 2018, 23, 149-154.	1.0	5
800	Platelet reactivity-adjusted antiplatelet therapy in patients with percutaneous coronary intervention: a meta-analysis of randomized controlled trials. Platelets, 2018, 29, 589-595.	1.1	3
801	Nonâ€“ST-Segment Acute Coronary Syndromes. Cardiology Clinics, 2018, 36, 37-52.	0.9	39
802	Management of antiplatelet therapy in patients undergoing neuroendovascular procedures. Journal of Neurosurgery, 2018, 129, 890-905.	0.9	74
803	Changing Scenario in Management of Acute Coronary Syndromes in Femalesâ€”Evidence from Recent Studies. Indian Journal of Cardiovascular Disease in Women WINCARS, 2018, 03, 245-250.	0.1	1
804	Analysis of Bleeding Complications in Acute Coronary Syndrome: Comparison of Effect of Tirofiban in Diabetic and Non-Diabetic Patients. Journal of Clinical & Experimental Cardiology, 2018, 09, .	0.0	0
805	A Multicenter, Randomized, Double-Blind, and Placebo-Controlled Study of the Effects of Tongxinluo Capsules in Acute Coronary Syndrome Patients with High On-Treatment Platelet Reactivity. Chinese Medical Journal, 2018, 131, 508-515.	0.9	10
806	Individualized Antiplatelet Therapy. Chinese Medical Journal, 2018, 131, 1387-1389.	0.9	1
807	Antiplatelet agents in uncertain clinical scenariosâ€”a bleeding nightmare. Cardiovascular Diagnosis and Therapy, 2018, 8, 647-662.	0.7	7

#	Article	IF	Citations
808	Monitoring platelet function: what have we learned from randomized clinical trials?. Cardiovascular Diagnosis and Therapy, 2018, 8, 621-629.	0.7	5
809	Medical Therapy for Long-Term Prevention of Atherothrombosis Following an Acute Coronary Syndrome. Journal of the American College of Cardiology, 2018, 72, 2886-2903.	1.2	68
810	ACC/AHA Versus ESC Guidelines on DualÂAntiplatelet Therapy. Journal of the American College of Cardiology, 2018, 72, 2915-2931.	1.2	273
811	Impact of genetic polymorphisms on platelet function and response to anti platelet drugs. Cardiovascular Diagnosis and Therapy, 2018, 8, 610-620.	0.7	14
812	Recent progress and market analysis of anticoagulant drugs. Journal of Thoracic Disease, 2018, 10, 2011-2025.	0.6	29
813	Predictors and Management of Antiplatelet-Related Bleeding Complications for Acute Coronary Syndrome in Chinese Elderly Patients. Cellular Physiology and Biochemistry, 2018, 50, 1164-1177.	1.1	3
814	Effect of tailored use of tirofiban in patients with Non-ST-elevation acute coronary syndrome undergoing percutaneous coronary intervention: a randomized controlled trial. BMC Cardiovascular Disorders, 2018, 18, 201.	0.7	3
815	Association of platelet response to cilostazol with clinical outcome and CYP genotype in patients with cerebral infarction. Thrombosis Research, 2018, 172, 14-20.	0.8	2
816	Evaluation of Acute In-stent Thrombosis during Stent-assisted Coil Embolization of Unruptured Intracranial Aneurysms. Neurologia Medico-Chirurgica, 2018, 58, 435-441.	1.0	11
817	Adverse clinical outcomes associated with double dose clopidogrel compared to the other antiplatelet regimens in patients with coronary artery disease: a systematic review and meta-analysis. BMC Pharmacology & Toxicology, 2018, 19, 54.	1.0	4
818	Optimal duration of dual antiplatelet therapy after PCI: integrating procedural complexity, bleeding risk and the acuteness of clinical presentation. Expert Review of Cardiovascular Therapy, 2018, 16, 735-748.	0.6	8
819	The Evolving Concept of Dual Antiplatelet Therapy after Percutaneous Coronary Intervention: Focus on Unique Feature of East Asian and â€œAsian Paradoxâ€• Korean Circulation Journal, 2018, 48, 537.	0.7	52
820	Acute Coronary Syndrome. , 2018, , 147-161.		2
821	Laboratory monitoring of P2Y12 inhibitors: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2018, 16, 2341-2346.	1.9	11
822	Modern Antiplatelet Therapy: When Is Clopidogrel the Right Choice?. Cardiovascular Innovations and Applications, 2018, 3, .	0.1	0
823	Novel aspects of antiplatelet therapy in cardiovascular disease. Research and Practice in Thrombosis and Haemostasis, 2018, 2, 439-449.	1.0	41
824	Novel Antiplatelet Agents. , 2018, , 391-415.		1
825	Vasodilator-stimulated phosphoprotein-guided Clopidogrel maintenance therapy reduces cardiovascular events in atrial fibrillation patients requiring anticoagulation therapy and scheduled for percutaneous coronary intervention: a prospective cohort study. BMC Cardiovascular Disorders, 2018, 18, 120.	0.7	7

#	Article	IF	Citations
826	Acute myocardial infarction occurring while on chronic clopidogrel therapy (â€˜clopidogrel failureâ€™) is associated with high incidence of clopidogrel poor responsiveness and stent thrombosis. PLoS ONE, 2018, 13, e0195504.	1.1	2
827	Strategies in Acute Coronary Syndrome. , 2018, , 921-938.		2
828	Pharmacogenetic association study on clopidogrel response in Puerto Rican Hispanics with cardiovascular disease: a novel characterization of a Caribbean population. Pharmacogenomics and Personalized Medicine, 2018, Volume 11, 95-106.	0.4	7
829	Laboratory coagulation tests. , 2018, , 47-56.		0
830	Peri-Procedural Platelet Reactivity in Percutaneous Coronary Intervention. Thrombosis and Haemostasis, 2018, 118, 1131-1140.	1.8	11
831	Effect of intra-coronary administration of tirofiban through aspiration catheter on patients over 60 years with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention. Medicine (United States), 2018, 97, e10850.	0.4	5
832	Never So Simple. JACC: Cardiovascular Interventions, 2018, 11, 1287-1289.	1.1	0
833	Individual long-term variation of platelet reactivity in patients with dual antiplatelet therapy after myocardial infarction. Platelets, 2019, 30, 572-578.	1.1	3
834	Comparison of factors affecting platelet reactivity in various platelet function tests. Platelets, 2019, 30, 631-636.	1.1	18
835	Antiplatelet Therapy Bridging With Cangrelor in Patients With Coronary Stents: A Case Series. Annals of Pharmacotherapy, 2019, 53, 171-177.	0.9	19
836	The safety of triple antiplatelet therapy under thromboelastography guidance in patients undergoing stenting for ischemic cerebrovascular disease. Journal of NeuroInterventional Surgery, 2019, 11, 352-356.	2.0	19
837	The Role of Novel Oral Anticoagulants and Antiplatelet Therapy after Percutaneous Coronary Intervention: Individualizing Therapy to Optimize Outcomes. Korean Circulation Journal, 2019, 49, 645.	0.7	3
838	Association Between Residual Platelet Reactivity on Clopidogrel Treatment and Severity of Coronary Atherosclerosis: Intrinsic Hypercoagulability as a Mediator. Advances in Therapy, 2019, 36, 2296-2309.	1.3	4
839	Relationship of Platelet Reactivity and Inflammatory Markers to Recurrent Adverse Events in Patients with ST-Elevation Myocardial Infarction. Thrombosis and Haemostasis, 2019, 119, 1785-1794.	1.8	11
840	Towards Personalized Antithrombotic Treatments: Focus on P2Y12 Inhibitors and Direct Oral Anticoagulants. Clinical Pharmacokinetics, 2019, 58, 1517-1532.	1.6	6
841	Updated Expert Consensus Statement on Platelet Function and Genetic Testing forÂGuiding P2Y12 Receptor Inhibitor Treatment in Percutaneous CoronaryÂIntervention. JACC: Cardiovascular Interventions, 2019, 12, 1521-1537.	1.1	366
842	Gender and Outcomes following Guided De-Escalation of Antiplatelet Treatment in Acute Coronary Syndrome Patients: The TROPICAL-ACS Gender Substudy. Thrombosis and Haemostasis, 2019, 119, 1527-1538.	1.8	7
843	Shear-induced platelet aggregation: 3D-grayscale microfluidics for repeatable and localized occlusive thrombosis. Biomicrofluidics, 2019, 13, 054106.	1.2	13

#	Article	IF	Citations
844	Concomitant assessment of rivaroxaban concentration and its impact on thrombin generation. Thrombosis Research, 2019, 184, 8-15.	0.8	4
845	Reasons for the Failure of Platelet Function Testing to Adjust Antiplatelet Therapy. Circulation: Cardiovascular Interventions, 2019, 12, e007749.	1.4	2
846	Personalized antiplatelet therapy in patients with coronary artery disease undergoing percutaneous coronary intervention: A network metaâ€analysis of randomized clinical trials. Catheterization and Cardiovascular Interventions, 2019, 94, 181-186.	0.7	5
847	Foreword: A Brief History of Ideas About Platelets in Health and Disease. , 2019, , xv-xxxviii.		1
848	Effects of the rs2244613 polymorphism of the CES1 gene on the antiplatelet effect of the receptor P2Y12 blocker clopidogrel. Drug Metabolism and Personalized Therapy, 2019, 34, .	0.3	5
849	Cardiovascular Risk Reduction. Critical Care Nursing Clinics of North America, 2019, 31, 15-30.	0.4	2
850	High and low on-treatment platelet reactivity to P2Y12 inhibitors in a contemporary cohort of acute coronary syndrome patients undergoing percutaneous coronary intervention. Thrombosis Research, 2019, 175, 95-101.	0.8	14
851	The clinical effects of CYP2C19 *2 allele frequency on Palestinian patients receiving clopidogrel after percutaneous coronary intervention. International Journal of Clinical Pharmacy, 2019, 41, 96-103.	1.0	6
852	Tailored P2Y12 inhibitor treatment in patients undergoing non-urgent PCIâ€"the POPular Risk Score study. European Journal of Clinical Pharmacology, 2019, 75, 1201-1210.	0.8	16
853	Personalised antiplatelet therapy based on pharmacogenomics in acute ischaemic minor stroke and transient ischaemic attack: study protocol for a randomised controlled trial. BMJ Open, 2019, 9, e028595.	0.8	3
854	Antiplatelet therapy for tibial balloon angioplasty: A clinical perspective. SAGE Open Medicine, 2019, 7, 205031211985457.	0.7	0
855	Variation in platelet expression of FcÎ³RIIa after myocardial infarction. Journal of Thrombosis and Thrombolysis, 2019, 48, 88-94.	1.0	6
856	A brief review on resistance to P2Y12 receptor antagonism in coronary artery disease. Thrombosis Journal, 2019, 17, 11.	0.9	46
857	Half-dose ticagrelor versus high-dose clopidogrel in reducing platelet reactivity in acute coronary syndrome patients with high on-clopidogrel platelet reactivity (divide study). European Journal of Clinical Pharmacology, 2019, 75, 1059-1068.	0.8	11
858	Clopidogrel Pharmacogenetics. Circulation: Cardiovascular Interventions, 2019, 12, e007811.	1.4	139
859	Switching to Clopidogrel in Patients With Acute Coronary Syndrome Managed With Percutaneous Coronary Intervention Initially Treated With Prasugrel or Ticagrelor: Systematic Review and Meta-analysis. Annals of Pharmacotherapy, 2019, 53, 997-1004.	0.9	3
860	Platelet reactivity and clinical outcomes in acute coronary syndrome patients treated with prasugrel and clopidogrel: a pre-specified exploratory analysis from the TROPICAL-ACS trial. European Heart Journal, 2019, 40, 1942-1951.	1.0	41
861	Pharmacodynamic changes of platelet reactivity status in patients with chronic kidney disease after coronary artery stenting. Biomedicine and Pharmacotherapy, 2019, 113, 108773.	2.5	3

#	Article	IF	Citations
862	Laboratory Monitoring of Antiplatelet Therapy. , 2019, , 653-682.		0
863	Platelet Function Testing in Clinical Research Trials. , 2019, , 683-700.		0
864	Contractile forces in platelet aggregates under microfluidic shear gradients reflect platelet inhibition and bleeding risk. Nature Communications, 2019, 10, 1204.	5.8	69
865	Comparisons between ticagrelor and clopidogrel following percutaneous coronary intervention in patients with acute coronary syndrome: a comprehensive meta-analysis . Drug Design, Development and Therapy, 2019, Volume 13, 719-730.	2.0	21
866	P2Y12 Antagonists. , 2019, , 937-956.		1
867	Antiplatelet Drugs in the Management of Thrombotic/Ischemic Events in Children. , 2019, , 1079-1083.		4
868	De-escalation of anti-platelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention. Chinese Medical Journal, 2019, 132, 197-210.	0.9	11
869	Periprocedural Neuroendovascular Antiplatelet Strategies for Thrombosis Prevention in Clopidogrelâ€Hyporesponsive Patients. Pharmacotherapy, 2019, 39, 317-334.	1.2	14
870	Clinical Utility of CYP2C19 Genotyping to Guide Antiplatelet Therapy in Patients With an Acute Coronary Syndrome or Undergoing Percutaneous Coronary Intervention. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 647-652.	1.1	65
871	Platelet MicroRNA 365-3p Expression Correlates with High On-treatment Platelet Reactivity in Coronary Artery Disease Patients. Cardiovascular Drugs and Therapy, 2019, 33, 129-137.	1.3	17
872	Platelet Function Testing and ClinicalÂOutcomes. JACC Basic To Translational Science, 2019, 4, 776-777.	1.9	0
873	Monitoring Platelet Function in Children With Ventricular Assist Devices: The Devil Is in the Details. ASAIO Journal, 2019, 65, 104-105.	0.9	0
874	Measuring high on-treatment platelet reactivity in clinical practice; should we use a panel of platelet function tests?. Blood Coagulation and Fibrinolysis, 2019, 30, 263-269.	0.5	3
875	Laser speckle decorrelation time-based platelet function testing in microfluidic system. Scientific Reports, 2019, 9, 16514.	1.6	10
876	Platelet Reactivity in Patients on Aspirin and Clopidogrel Therapy Measured by a New Bedside Whole-Blood Assay. Journal of Cardiovascular Pharmacology, 2019, 73, 40-47.	0.8	14
877	Stratified Approaches to Antiplatelet Therapies Based on Platelet Reactivity Testing. Frontiers in Cardiovascular Medicine, 2019, 6, 176.	1.1	17
878	Precision of VerifyNow P2Y12 Assessment of Clopidogrel Response in Patients Undergoing Cerebral Aneurysm Flow Diversion. Neurosurgery, 2019, 85, 543-549.	0.6	30
879	Oral antiplatelets in primary and secondary prevention of myocardial infarction: a review. Irish Journal of Medical Science, 2019, 188, 453-467.	0.8	4

#	Article	IF	Citations
880	Coronary blood flow volume change is negatively associated with platelet aggregability in patients with non-obstructive ischemic heart disease who have no anti-platelet agents. International Journal of Cardiology, 2019, 277, 3-7.	0.8	1
881	Emergency transâ€catheter coronary intervention for left main compression secondary to pulmonary hypertension in a 4â€yearâ€old child. Catheterization and Cardiovascular Interventions, 2019, 93, 105-107.	0.7	5
882	Biomarkers for Antiplatelet Therapy. , 2019, , 139-148.		0
883	Antiplatelet Therapy Monitoring in Neonates and Children. Seminars in Thrombosis and Hemostasis, 2019, 45, 073-085.	1.5	4
884	Role of CYP2C19 alleles in the management of recurrent ischemic stroke. Neurology: Clinical Practice, 2019, 9, 140-144.	0.8	3
885	CYP2C19 pharmacogenetics versus standard of care dosing for selecting antiplatelet therapy in patients with coronary artery disease: A metaâ€analysis of randomized clinical trials. Catheterization and Cardiovascular Interventions, 2019, 93, 1246-1252.	0.7	27
887	Management of antiplatelet therapy for non-elective invasive procedures or bleeding complications: Proposals from the French Working Group on Perioperative Haemostasis (GIHP) and the French Study Group on Thrombosis and Haemostasis (GFHT), in collaboration with the French Society for Anaesthesia and Intensive Care (SFAR). Archives of Cardiovascular Diseases, 2019, 112, 199-216.	0.7	20
888	Assessment of Platelet REACtivity After Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2019, 12, 22-32.	1.1	48
889	Platelet Aggregability as a Predictor of Restenosis Following Carotid Endarterectomy. Journal of Stroke and Cerebrovascular Diseases, 2019, 28, 665-671.	0.7	2
890	Management of antiplatelet therapy for non elective invasive procedures of bleeding complications: proposals from the French working group on perioperative haemostasis (GIHP), in collaboration with the French Society of Anaesthesia and Intensive Care Medicine (SFAR). Anaesthesia, Critical Care & Pain Medicine, 2019, 38, 289-302.	0.6	25
891	Endogenous fibrinolysis in STEMI: important before and after primary PCI. European Heart Journal, 2019, 40, 306-308.	1.0	6
892	Impact of Point-of-Care Platelet Function Testing Among Patients With and Without Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents (from the) Tj ETQq1 1 0.784314 rgBT /Overloc	0.7	
893	Antiplatelet Therapy in Cardiovascular Medicine. , 2019, , 396-414.		0
894	Monitoring of Antiplatelet Therapy in Children on Ventricular Assist Device Support: Comparison of Multiplate and Thromboelastography Platelet Mapping. ASAIO Journal, 2019, 65, 84-93.	0.9	13
895	Dual Antiplatelet Therapy Combining Aspirin and Ticagrelor for Intracranial Stenting Procedures: A Retrospective Single Center Study of 154 Consecutive Patients With Unruptured Aneurysms. Neurosurgery, 2019, 84, 77-83.	0.6	41
896	The effect of smoking on residual platelet reactivity to clopidogrel: a systematic review and meta-analysis. Platelets, 2020, 31, 3-14.	1.1	6
897	Thrombin-induced platelet aggregation â^'effect of dabigatran using automated platelet aggregometryâ^'. Platelets, 2020, 31, 360-364.	1.1	7
898	Clinical Evaluation of the Tolerability, Pharmacokinetics, and Inhibition of Platelet Aggregation of Eptifibatide in Healthy Chinese Subjects. Clinical Pharmacology in Drug Development, 2020, 9, 267-276.	0.8	1

#	Article	IF	Citations
899	Optimal duration of dual antiplatelet therapy post percutaneous coronary intervention in acute coronary syndrome. Trends in Cardiovascular Medicine, 2020, 30, 198-202.	2.3	4
900	Personalized antiplatelet therapy guided by a novel detection of platelet aggregation function in stable coronary artery disease patients undergoing percutaneous coronary intervention: a randomized controlled clinical trial. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 211-221.	1.4	36
901	Outcome of intracranial flow diversion according to the antiplatelet regimen used: a systematic review and meta-analysis. Journal of NeuroInterventional Surgery, 2020, 12, 148-155.	2.0	33
902	Impact of high onâ€treatment platelet reactivity on outcomes following PCI in patients on hemodialysis: An ADAPTâ€DES substudy. Catheterization and Cardiovascular Interventions, 2020, 96, 793-801.	0.7	6
903	Impact of Continuous P2Y12 Inhibition Tailoring in Acute Coronary Syndrome and Genetically Impaired Clopidogrel Absorption. Journal of Cardiovascular Pharmacology, 2020, 75, 174-179.	0.8	3
904	Ticagrelor versus clopidogrel in acute myocardial infarction patients with multivessel disease; From Korea Acute Myocardial Infarction Registry-National Institute of Health. Journal of Cardiology, 2020, 75, 478-484.	0.8	10
905	Smoking and outcomes following guided de-escalation of antiplatelet treatment in acute coronary syndrome patients: a substudy from the randomized TROPICAL-ACS trial. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 372-381.	1.4	7
906	Acute thrombosis of everolimus-eluting platinum chromium stent caused by impaired prasugrel metabolism due to cytochrome P450 enzyme 2B6*2 (C64T) polymorphism: a case report. European Heart Journal - Case Reports, 2020, 4, 1-7.	0.3	3
907	When to Believe Unexpected Results for Ticagrelor or Prasugrel. JACC: Cardiovascular Interventions, 2020, 13, 2248-2250.	1.1	3
908	High glycated albumin is an independent predictor of low response to clopidogrel in ACS patients: a cross-sectional study. Cardiovascular Diabetology, 2020, 19, 171.	2.7	14
909	Antithrombotic Therapy in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. Cardiology Clinics, 2020, 38, 551-561.	0.9	2
910	Antithrombotic Therapy: Prevention and Treatment of Atherosclerosis and Atherothrombosis. Handbook of Experimental Pharmacology, 2020, , 1.	0.9	10
911	Implementing a pharmacogenetic-driven algorithm to guide dual antiplatelet therapy (DAPT) in Caribbean Hispanics: protocol for a non-randomised clinical trial. BMJ Open, 2020, 10, e038936.	0.8	10
912	Assessment of platelet function utilizing viscoelastic testing. Transfusion, 2020, 60, S10-S20.	0.8	4
913	Effectiveness and safety of high dose clopidogrel plus aspirin in ischemic stroke patients with the single CYP2C19 loss-of-function allele: a randomized trial. BMC Neurology, 2020, 20, 395.	0.8	2
914	De-Escalation of Antiplatelet Treatment in Patients with Myocardial Infarction Who Underwent Percutaneous Coronary Intervention: A Review of the Current Literature. Journal of Clinical Medicine, 2020, 9, 2983.	1.0	9
915	CYP2C19 Genotyping to Guide Antiplatelet Therapy After Percutaneous Coronary Interventions. JAMA - Journal of the American Medical Association, 2020, 324, 747.	3.8	7
916	Whole blood dynamic platelet aggregation counting and 1-year clinical outcomes in patients with coronary heart diseases treated with clopidogrel. Platelets, 2021, 32, 968-974.	1.1	3

#	Article	IF	Citations
917	Relationship Between Platelet Reactivity and Ischemic and Bleeding Events After Percutaneous Coronary Intervention in East Asian Patients: 1â€Year Results of the PENDULUM Registry. Journal of the American Heart Association, 2020, 9, e015439.	1.6	35
918	Impact of Routine Platelet Reactivity Testing with VerifyNow Assay on Antiplatelet Choice After Percutaneous Coronary Intervention . Clinical Pharmacology: Advances and Applications, 2020, Volume 12, 35-41.	0.8	2
919	Platelet function/reactivity testing and prediction of risk of recurrent vascular events and outcomes after TIA or ischaemic stroke: systematic review and meta-analysis. Journal of Neurology, 2020, 267, 3021-3037.	1.8	16
920	Performance comparison of platelet function analyzers in cardiology patients: VerifyNow and Anysis-200 aspirin assays. Clinical Hemorheology and Microcirculation, 2020, 76, 33-42.	0.9	6
921	Platelet-Derived Thrombogenicity Measured by Total Thrombus-Formation Analysis System in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Circulation Journal, 2020, 84, 975-984.	0.7	5
922	Impacts of CYP2C19 Polymorphism and Clopidogrel Dosing on in-Stent Restenosis: A Retrospective Cohort Study in Chinese Patients . Drug Design, Development and Therapy, 2020, Volume 14, 669-676.	2.0	4
923	Serum interleukin-18 levels as a predictor for patients with genetic dysfunction of cytochrome P450 2C19 in dual antiplatelet therapy with clopidogrel. Journal of Cardiology, 2020, 76, 479-486.	0.8	1
924	Smoking and antiplatelet therapy after acute coronary syndromes. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 382-383.	1.4	0
925	Clinical Implications of â€œTailoredâ€•Antiplatelet Therapy in Patients With Chronic Total Occlusion. Journal of the American Heart Association, 2020, 9, e014676.	1.6	9
926	Platelet Inhibition in Acute Coronary Syndrome and Percutaneous Coronary Intervention: Insights from the Past and Present. Thrombosis and Haemostasis, 2020, 120, 565-578.	1.8	20
927	Routine CYP2C19 Genotyping to AdjustÂThienopyridine Treatment AfterÂPrimaryÂPCI for STEMI. JACC: Cardiovascular Interventions, 2020, 13, 621-630.	1.1	28
928	Derivation, Validation, and PrognosticÂUtility of a Prediction Rule for Nonresponse to Clopidogrel. JACC: Cardiovascular Interventions, 2020, 13, 606-617.	1.1	90
929	Effect of Smoking Cessation on the Pharmacokinetics and Pharmacodynamics of Clopidogrel after PCI: The Smoking Cessation Paradox Study. Thrombosis and Haemostasis, 2020, 120, 449-456.	1.8	10
930	Platelet Function Test Use for Patients with Coronary Artery Disease in the Early 2020s. Journal of Clinical Medicine, 2020, 9, 194.	1.0	12
931	Assessing platelet reactivity after drug eluting stent implantation: state of the art. Expert Review of Cardiovascular Therapy, 2020, 18, 17-24.	0.6	1
932	Platelet function testing guided antiplatelet therapy reduces cardiovascular events in Chinese patients with STâ€segment elevation myocardial infarction undergoing percutaneous coronary intervention: The PATROL study. Catheterization and Cardiovascular Interventions, 2020, 95, 598-605.	0.7	14
933	Platelet Function Testing with a VerifyNow-Directed Personalized Antiplatelet Strategy and Associated Rates of Thromboembolic Complications After Pipeline Embolization for Complex Cerebral Aneurysms. World Neurosurgery, 2020, 138, e674-e682.	0.7	11
934	The Role of Clopidogrel in 2020: A Reappraisal. Cardiovascular Therapeutics, 2020, 2020, 1-12.	1.1	55

#	Article	IF	Citations
935	World Heart Federation Expert Consensus Statement on Antiplatelet Therapy in East Asian Patients with ACS or Undergoing PCI. Global Heart, 2020, 9, 457.	0.9	34
936	Loading doses of ticagrelor versus clopidogrel in preventing periprocedural myocardial infarction in Asian patients with acute coronary syndrome. Perfusion (United Kingdom), 2021, 36, 122-129.	0.5	2
937	Mechanistic Insights to Target Atherosclerosis Residual Risk. Current Problems in Cardiology, 2021, 46, 100432.	1.1	21
938	Multiplex allele-specific detection of clinically important CYP2C19 variants associated with clopidogrel metabolism in a Bangladeshi population sample. Meta Gene, 2021, 27, 100830.	0.3	1
939	Validation of the ABCD-GENE score to identify high platelet reactivity in east Asian patients undergoing percutaneous coronary intervention. International Journal of Cardiology, 2021, 327, 15-18.	0.8	18
940	2020 ACC Expert Consensus Decision Pathway for Anticoagulant and Antiplatelet Therapy in Patients With Atrial Fibrillation or Venous Thromboembolism Undergoing Percutaneous Coronary Intervention or With Atherosclerotic Cardiovascular Disease. Journal of the American College of Cardiology, 2021, 77, 629-658.	1.2	144
941	CHADS2 and CHA2DS2-VASc scores as predictors of platelet reactivity in acute coronary syndrome. Journal of Cardiology, 2021, 77, 375-379.	0.8	6
942	Is a personalized pharmacotherapeutic approach closed for acute coronary syndrome?. Expert Opinion on Pharmacotherapy, 2021, 22, 527-529.	0.9	0
943	Standard vs. Modified Antiplatelet Therapy Based on Thromboelastography With Platelet Mapping for Preventing Bleeding Events in Patients Undergoing Stent-Assisted Coil for a Ruptured Intracranial Aneurysm. Frontiers in Neurology, 2020, 11, 615829.	1.1	14
944	Clinical risk scores: a tool to understand bleeding and thrombotic risk. , 2021, , 145-166.		0
945	Efficacy of Monitoring for Multiple Antiplatelet Therapy during Intracranial Stent Placement: A Preliminary Study. Journal of Neuroendovascular Therapy, 2021, 15, 533-539.	0.1	0
946	The influence of acute coronary syndrome on the levels of clopidogrel active metabolite and platelet inhibition in patients with and without CYP2C19 and ABCB1 gene polymorphisms. Postepy W Kardiologii Interwencyjnej, 2021, 17, 179-186.	0.1	1
947	Is This a Good Time to Revisit theÂTropics?. JACC: Cardiovascular Interventions, 2021, 14, 428-430.	1.1	1
948	Use of Thromboelastography Platelet Mapping for Assessment of Individual Platelet Response Secondary to Oral Antiplatelet Therapy after Percutaneous Coronary Intervention: An Attempt to Start Personalized Antiplatelet Therapy in India. Journal of Cardiac Critical Care TSS, 0, , .	0.0	0
949	Endothelial Shear Stress and Platelet FcÎ³RIIa Expression in Intracranial Atherosclerotic Disease. Frontiers in Neurology, 2021, 12, 646309.	1.1	1
950	Stent Thrombosis Risk Over Time on the Basis of Clinical Presentation and PlateletÂReactivity. JACC: Cardiovascular Interventions, 2021, 14, 417-427.	1.1	19
951	Independent predictors of acute kidney injury in patients with acute coronary syndrome after percutaneous coronary intervention. PLoS ONE, 2021, 16, e0247304.	1.1	4
952	Does Platelet Reactivity Testing Predict Post-Operative Bleeding Risk?. Journal of the American College of Cardiology, 2021, 77, 1287-1289.	1.2	1

#	Article	IF	Citations
953	Guided P2Y12 inhibitor therapy after percutaneous coronary intervention. Lancet, The, 2021, 397, 1423-1425.	6.3	8
954	MicroRNA as Potential Biomarkers of Platelet Function on Antiplatelet Therapy: A Review. Frontiers in Physiology, 2021, 12, 652579.	1.3	25
955	Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. Lancet, The, 2021, 397, 1470-1483.	6.3	133
956	Assessing the Risks of Bleeding vs Thrombotic Events in Patients at High Bleeding Risk After Coronary Stent Implantation. JAMA Cardiology, 2021, 6, 410.	3.0	52
957	Analysis of individualized antiplatelet therapy for patients of acute coronary syndrome after percutaneous coronary intervention under the guidance of platelet function. Medicine (United) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 57	0.4	
958	PHARMACOGENETIC BASES OF INDIVIDUAL SENSITIVITY AND PERSONALIZED ADMINISTRATION OF ANTIPLATELET THERAPY IN DIFFERENT ETHNIC GROUPS. Farmatsiya I Farmakologiya, 2021, 8, 392-404.	0.2	2
959	Genetic testing in patients undergoing percutaneous coronary intervention: rationale, evidence and practical recommendations. Expert Review of Clinical Pharmacology, 2021, 14, 963-978.	1.3	27
960	MiR-126-3p and MiR-223-3p as Biomarkers for Prediction of Thrombotic Risk in Patients with Acute Myocardial Infarction and Primary Angioplasty. Journal of Personalized Medicine, 2021, 11, 508.	1.1	17
961	Long-term complications after stent assist coiling dependent on clopidogrel response. BMC Neurology, 2021, 21, 247.	0.8	8
962	The Current Role of Platelet Function Testing in Clinical Practice. Seminars in Thrombosis and Hemostasis, 2021, 47, 843-854.	1.5	6
963	Is platelet function testing at the acute phase under P2Y12 inhibitors helpful in predicting bleeding in real-life patients with acute coronary syndrome? The AVALANCHE study. Archives of Cardiovascular Diseases, 2021, 114, 612-623.	0.7	0
964	Ticagrelor versus Clopidogrel in the Dual Antiplatelet Regimen for Intracranial Stenting or Flow-Diverter Treatment for Unruptured Cerebral Aneurysms: A Single-Center Cohort Study. American Journal of Neuroradiology, 2021, 42, 1638-1644.	1.2	27
965	Use of Thromboelastography Platelet Mapping for Assessment of Individual Platelet Response Secondary to Oral Antiplatelet Therapy after Percutaneous Coronary Intervention: An Attempt to Start Personalized Antiplatelet Therapy in India. Journal of Cardiac Critical Care TSS, 2021, 5, 108-113.	0.0	1
966	Author's reply. Journal of Cardiology, 2021, 78, 88-89.	0.8	0
967	Diretrizes da Sociedade Brasileira de Cardiologia sobre Angina InstÃ¡vel e Infarto Agudo do MiocÃ¡rdio sem SupradesnÃvel do Segmento ST â€“ 2021. Arquivos Brasileiros De Cardiologia, 2021, 117, 181-264.	0.3	45
968	Sex-based outcomes in contemporary antiplatelet therapy trials. Open Heart, 2021, 8, e001761.	0.9	4
969	Platelet Function Testing and Genotyping for Tailoring Treatment in Complex PCI Patients. US Cardiology Review, 0, 15, .	0.5	1
970	PON1 Q192R is associated with high platelet reactivity with clopidogrel in patients undergoing elective neurointervention: A prospective single-center cohort study. PLoS ONE, 2021, 16, e0254067.	1.1	1

#	Article	IF	Citations
971	Redefining residual inflammatory risk after acute coronary syndrome. Future Cardiology, 2022, 18, 115-123.	0.5	2
972	Severe, Intolerable Fatigue Associated with Hyperresponse to Clopidogrel. World Neurosurgery, 2021, 156, e374-e380.	0.7	1
973	Platelet Function Testing Is Required for Intracranial Stent Placement. Stroke, 2021, 52, 3826-3828.	1.0	0
974	Antithrombotic Management for Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. Rational Pharmacotherapy in Cardiology, 2021, 17, 628-637.	0.3	0
975	Antiplatelet strategies in acute coronary syndromes: design and methodology of an international collaborative network meta-analysis of randomized controlled trials. Minerva Cardiology and Angiology, 2021, 69, 398-407.	0.4	2
976	Effect of Adjusted Antiplatelet Therapy on Preventing Ischemic Events After Stenting for Intracranial Aneurysms. Stroke, 2021, 52, 3815-3825.	1.0	24
977	Antithrombotic therapy in high-risk patientsÂafter percutaneous coronary intervention; study design, cohort profile and incidence of adverse events. Netherlands Heart Journal, 2021, 29, 525-535.	0.3	2
978	Multiparameter phenotyping of platelet reactivity for stratification of human cohorts. Blood Advances, 2021, 5, 4017-4030.	2.5	14
979	Differential Impact of Cytochrome 2C19 Allelic Variants on Three Different Platelet Function Tests in Clopidogrel-Treated Patients. Journal of Clinical Medicine, 2021, 10, 3992.	1.0	1
980	Periprocedural Variability of Platelet Functions in Carotid Artery Stenting: An Analysis Using VerifyNow. Journal of Neuroendovascular Therapy, 2021, 15, 505-516.	0.1	0
981	Platelet Inhibitor Agents. , 2012, , 97-112.		2
982	Meta-analysis Comparing Outcomes of Type 2 Myocardial Infarction and Type 1 Myocardial Infarction With a Focus on Dual Antiplatelet Therapy. CJC Open, 2020, 2, 118-128.	0.7	9
983	Oral antiplatelet agents in cardiovascular disease. Vasa - European Journal of Vascular Medicine, 2019, 48, 291-302.	0.6	14
984	Net platelet clot strength of thromboelastography platelet mapping assay for the identification of high on-treatment platelet reactivity in post-PCI patients. Bioscience Reports, 2020, 40, .	1.1	4
985	Evolution of antithrombotic therapy in patients undergoing percutaneous coronary intervention: a 40-year journey. European Heart Journal, 2021, 42, 339-351.	1.0	57
986	Platelet Function Testing for Cardiac Surgery Patients on Antiplatelet Therapy: The Extreme Variability of Point-Of-Care Tests. Biomedical and Pharmacology Journal, 2018, 11, 593-607.	0.2	3
987	High Platelet Reactivity in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: Randomised Controlled Trial Comparing Prasugrel and Clopidogrel. PLoS ONE, 2015, 10, e0135037.	1.1	12
988	A Study of Platelet Inhibition, Using a â€˜Point of Careâ€™ Platelet Function Test, following Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction [PINPOINT-PPCI]. PLoS ONE, 2015, 10, e0144984.	1.1	13

#	Article	IF	Citations
989	Antiplatelet Therapy of Cilostazol or Sarpogrelate with Aspirin and Clopidogrel after Percutaneous Coronary Intervention: A Retrospective Cohort Study Using the Korean National Health Insurance Claim Database. PLoS ONE, 2016, 11, e0150475.	1.1	12
990	Incidence and Clinical Features of Early Stent Thrombosis in the Era of New P2y12 Inhibitors (PLATIS-2). PLoS ONE, 2016, 11, e0157437.	1.1	5
991	Dual Antiplatelet Therapy in Coronary Artery Disease: Comparison Between ACC/AHA 2016 and ESC 2017 Guidelines. European Cardiology Review, 2020, 15, 1-3.	0.7	8
994	PHARMACOGENETICS OF ANTITHROMBOTIC DRUGS: STATUS UPDATE ON THE PROBLEM. Atherothrombosis, 2018, , 115-129.	0.1	2
995	Clopidogrel. American Journal of Cardiovascular Drugs, 2012, 12, 361-374.	1.0	7
996	Clopidogrel Resistance in Lower Extremity Arterial Endovascular Interventions. Current Pharmaceutical Design, 2019, 24, 4554-4557.	0.9	3
997	Potential Usefulness of Clopidogrel Pharmacogenetics in Ce rebral Endovascular Procedures and Carotid Artery Stenting. Current Clinical Pharmacology, 2017, 12, 11-17.	0.2	16
998	Prasugrel (EfientÂ®) with percutaneous coronary intervention for treating acute coronary syndromes (review of TA182): systematic review and economic analysis. Health Technology Assessment, 2015, 19, 1-130.	1.3	5
999	The Efficacy of P2Y12 Reactive Unit to Predict the Periprocedural Thromboembolic and Hemorrhagic Complications According to Clopidogrel Responsiveness and Safety of Modification of Dual Antiplatelet Therapy : A Meta-Analysis. Journal of Korean Neurosurgical Society, 2020, 63, 539-549.	0.5	7
1000	A Prospective Evaluation of Bleeding Risk of Interventional Techniques in Chronic Pain. Pain Physician, 2011, 4;14, 317-329.	0.3	45
1001	A pharmacodynamic study of the optimal P2Y₁₂ inhibitor regimen for East Asian patients with acute coronary syndrome. Korean Journal of Internal Medicine, 2015, 30, 620-628.	0.7	21
1002	Clopidogrel Resistance. Korean Journal of Medicine, 2013, 85, 1.	0.1	2
1003	High residual platelet reactivity on clopidogrel: its significance and therapeutic challenges overcoming clopidogrel resistance. Cardiovascular Diagnosis and Therapy, 2013, 3, 23-37.	0.7	25
1004	Temporal Variability of Platelet Reactivity in Patients Treated with Clopidogrel or Ticagrelor. Korean Circulation Journal, 2019, 49, 1052.	0.7	7
1005	Platelet reactivity and cardiovascular events after percutaneous coronary intervention in patients with stable coronary artery disease: the Stent Thrombosis In Belgium (STIB) trial. EuroIntervention, 2014, 10, 204-211.	1.4	18
1006	Platelet reactivity in comatose survivors of cardiac arrest undergoing percutaneous coronary intervention and hypothermia. EuroIntervention, 2015, 10, 1418-1424.	1.4	23
1007	2014 ESC/EACTS Guidelines on myocardial revascularization. EuroIntervention, 2015, 10, 1024-1094.	1.4	251
1008	Current status of high on-treatment platelet reactivity in patients with coronary or peripheral arterial disease: Mechanisms, evaluation and clinical implications. World Journal of Cardiology, 2015, 7, 912.	0.5	29

#	Article	IF	Citations
1009	Pharmacogenomic Testing and Antithrombotic Therapy: Ready for Prime Time?. Rambam Maimonides Medical Journal, 2013, 4, e0005.	0.4	5
1010	Elinogrel, an orally and intravenously available ADP-receptor antagonist. Hamostaseologie, 2012, 32, 191-194.	0.9	8
1011	Post percutaneous coronary intervention antiplatelet therapy: Current perceptions, prospects and perplexity. Cardiology Journal, 2011, 18, 712-717.	0.5	5
1013	Pharmacodynamic effects of loading of antiplatelets in acute stroke patients. Journal of Neuroendovascular Therapy, 2014, 8, 251-258.	0.1	3
1014	High On-Treatment Platelet Reactivity Predicts Cardiac Events in Patients with Drug-Eluting Stents. Arquivos Brasileiros De Cardiologia, 2013, 100, 221-8.	0.3	4
1015	P2Y12Platelet Receptors: Importance in Percutaneous Coronary Intervention. Arquivos Brasileiros De Cardiologia, 2013, 101, 277-82.	0.3	6
1017	An optimal window of platelet reactivity by LTA assay for patients undergoing percutaneous coronary intervention. Thrombosis Journal, 2021, 19, 73.	0.9	0
1018	Utility of a pharmacogenetic-driven algorithm in guiding dual antiplatelet therapy for patients undergoing coronary drug-eluting stent implantation in China. European Journal of Clinical Pharmacology, 2022, 78, 215-225.	0.8	2
1019	Application of Age, Body Mass Index, Chronic Kidney Disease, Diabetes, and Genotyping Score for Efficacy of Clopidogrel: Secondary Analysis of the CHANCE Trial. Stroke, 2022, 53, 465-472.	1.0	10
1020	Intensified antiplatelet therapy in patients after percutaneous coronary intervention with high onâ€treatment platelet reactivity: the OPTImal Management of Antithrombotic Agents (OPTIMA)â€2 Trial. British Journal of Haematology, 2021, , .	1.2	5
1021	Almanac 2011: Stable Coronary Artery Disease. the National Society Journals Present Selected Research That Has Driven Recent Advances in Clinical Cardiology. Materia Socio-medica, 2011, 23, 129.	0.3	0
1022	Characterization and Evaluation of Clopidogrel Response Testing in a Community Hospital Setting. Journal of Clinical & Experimental Cardiology, 2011, 02, .	0.0	0
1023	Pharmacogenomics: Tailoring Treatment Based on Genotype. , 2012, , 37-50.		0
1024	The Clinical Relevance of Response Variability to Antiplatelet Therapy. Hematology American Society of Hematology Education Program, 2011, 2011, 70-75.	0.9	0
1025	Stable angina pectoris. Srce I Krvni Sudovi, 2012, 31, 38-47.	0.1	0
1026	The Role of Laboratory Monitoring in Antiplatelet Therapy. Handbook of Experimental Pharmacology, 2012, , 471-494.	0.9	2
1027	Clinical significance of monitoring tests for anti-platelet drugs. Japanese Journal of Thrombosis and Hemostasis, 2012, 23, 352-357.	0.1	1
1028	Pharmacotherapy During Percutaneous Coronary Interventions. , 0, , .		0

#	Article	IF	Citations
1032	Almanac 2012: Cardiovascular risk scores: The national society journals present selected research that has driven recent advances in clinical cardiology. Srce I Krvni Sudovi, 2013, 32, 317-326.	0.1	0
1033	Issues Remaining in Current Neuroendovascular Therapy for Complex Aneurysms. Japanese Journal of Neurosurgery, 2013, 22, 749-758.	0.0	0
1034	Pharmacogenomics and Personalized Medicine of the Antiplatelet Drugs. , 2013, , 469-506.		0
1035	Almanac 2012: Interventional cardiology. Archivos De Cardiologia De Mexico, 2013, 83, 138-148.	0.1	0
1036	Personalised antiplatelet therapy: are we ready for prime time? Data from China. EuroIntervention, 2013, 9, 296-298.	1.4	3
1038	Antithrombotic Issues in Women. , 2014, , 321-357.		0
1039	Haemostatic failure. , 2014, , 1003-1016.e3.		0
1040	Implications of the VerifyNow P2Y12 Assay on Patient Outcomes. Open Journal of Thoracic Surgery, 2014, 04, 78-85.	0.1	1
1041	Progress of antiplatelet therapy. Nosotchu, 2014, 36, 210-215.	0.0	0
1042	Pharmacogenetic Testing for Anticoagulant and Antiplatelet Therapies. , 2015, , 173-181.		0
1043	Bedside-Monitoring der Blutgerinnung. , 2015, , 1-11.		0
1044	Platelet function test in patients with impaired renal function and coronary artery disease taking dual antiplatelet therapy. Journal of the Japanese Coronary Association, 2015, 21, 195-202.	0.0	0
1045	DAPT After Stenting in Stable and Acute Coronary Syndromes- Does the Drug Combination Really Matter?. , 2015, , 255-269.		0
1046	Shutdown reactivity of platelets to adenosine diphosphate anr arachidoic acid and its prognostic value in patients with myocardial infraction with elevation of ST segment. ScienceRise, 2015, 6, 81.	0.1	0
1047	Inerconnection of the change of vascular-trombocytic hemostasis parameters and sexual hormones level in women with the stable forms of ischemic heart disease in the period of postmenopause. ScienceRise, 2016, 1, 57.	0.1	0
1048	Outline of â€œRecommendations for the standardization of light transmission aggregometry: a consensus of the working party from the platelet physiology subcommittee of SSC/ISTHâ€• Japanese Journal of Thrombosis and Hemostasis, 2016, 27, 365-369.	0.1	2
1049	Peri- and Post-procedural Antithrombotic Therapy in Women. , 2017, , 73-100.		1
1051	Gerinnungsphysiologische Laboranalytik. , 2017, , 51-60.		0

#	Article	IF	Citations
1052	Impact of Antiplatelet Therapy and Platelet Reactivity Testing on Cardiovascular Outcomes in Patients with Chronic Kidney Disease. , 2017, , 301-313.		0
1053	Assessment of thrombogenicity in stroke. Japanese Journal of Thrombosis and Hemostasis, 2017, 28, 297-305.	0.1	0
1054	Influence of genetic factors regulating lipid metabolism on the outcomes of percutaneous coronary interventions. Kardiologiya I Serdechno-Sosudistaya Khirurgiya, 2018, 11, 4.	0.1	0
1055	FEMALE GENDER AS AN ADDITIONAL RISK FACTOR FOR ATHEROTHROMBOTIC COMPLICATIONS OF IHD. World of Medicine and Biology, 2018, 14, 065.	0.1	0
1056	Comparison of antiplatelet treatment in patients with clopidogrel nonresponders with or without carriage of CYP2C19 polymorphism. Korean Journal of Internal Medicine, 2018, , .	0.7	1
1057	On-treatment platelet reactivity in the era of new ADP receptor blockers: data from a real-world clinical practice. Acta Medica Martiniana, 2018, 18, 34-39.	0.4	1
1058	Effect of Blood Donation on the Donorâ€™s Hemorheological Properties. The Korean Journal of Blood Transfusion, 2018, 29, 229-239.	0.1	0
1060	Bedside-Monitoring der Blutgerinnung. Springer Reference Medizin, 2019, , 549-558.	0.0	0
1061	Diabetes and Cardiovascular Disease. , 2019, , 709-730.		1
1062	CYP2C19 Polymorphisms and Smoking Status Affects Responsiveness to the Platelet P2Y12 Receptor Antagonist Clopidogrel. Cardiovascular Prevention and Pharmacotherapy, 2019, 1, 63.	0.0	0
1063	Preliminary Experience of Preoperative Modification of Platelet Aggregation. Journal of Neuroendovascular Therapy, 2019, 13, 250-256.	0.1	2
1064	Clinical Markers of Clopidogrel Resistance in Percutaneous Coronary-Treated Patients. Konuralp Tip Dergisi, 0, , 55-61.	0.1	0
1065	Effectiveness of personalized antiplatelet therapy in patients undergoing coronary stenting: meta-analysis. Complex Issues of Cardiovascular Diseases, 2019, 8, 26-36.	0.3	1
1066	Personalised Approaches to Improving the Effect of Anti-platelet Agents: Where Do We Stand?. European Cardiology Review, 2019, 14, 179-180.	0.7	0
1067	(In what extent we reached the standards of antiplatelet therapy in secondary prevention of) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 182	0.1	0
1068	The role of clopidogrel in the current treatment of acute coronary syndrome. Atherothrombosis, 2020, , 72-81.	0.1	0
1069	Secondary prevention after acute coronary syndrome. Vnitrni Lekarstvi, 2020, 66, 236-241.	0.1	1
1070	Antiplatelet Therapy. Contemporary Cardiology, 2021, , 249-288.	0.0	0

#	Article	IF	Citations
1071	Antiplatelet strategies in acute coronary syndromes: design and methodology of an international collaborative network meta-analysis of randomized controlled trials. Minerva Cardiology and Angiology, 0, , .	0.4	0
1073	Monitoring and tailoring the P2Y12 ADP receptor blocker therapy. Vnitrni Lekarstvi, 2020, 66, e26-e33.	0.1	0
1074	Prevalence of aspirin and clopidogrel resistance in neurovascular stenting: a single-center experience. The European Research Journal, 2021, 7, 601-609.	0.1	0
1075	Antithrombotic therapy in patients with acute coronary syndromes: a balance between protection from ischemic events and risk of bleeding. American Journal of Cardiovascular Disease, 2011, 1, 255-63.	0.5	1
1076	Controversies in the use & implementation of drug-eluting stent technology. Indian Journal of Medical Research, 2012, 136, 926-41.	0.4	0
1077	Clopidogrel Resistance by P2Y12 Platelet Function Testing in Patients Undergoing Neuroendovascular Procedures: Incidence of Ischemic and Hemorrhagic Complications. Journal of Vascular and Interventional Neurology, 2013, 6, 26-34.	1.1	37
1078	Efficacy and safety of individually tailored antiplatelet therapy in patients with acute coronary syndrome after coronary stenting: a single center, randomized, feasibility study. Journal of Geriatric Cardiology, 2015, 12, 23-9.	0.2	5
1079	Efficacy and safety of cangrelor for patients with coronary artery disease: a meta-analysis of four randomized trials. International Journal of Clinical and Experimental Medicine, 2015, 8, 800-8.	1.3	2
1080	Efficacy and safety of different doses of tirofiban combined with ticagrelor on diabetic patients with AMI receiving in emergency percutaneous coronary intervention (PCI). International Journal of Clinical and Experimental Medicine, 2015, 8, 11360-9.	1.3	6
1081	Relationship between ADP-induced platelet-fibrin clot strength and anti-platelet responsiveness in ticagrelor treated ACS patients. Journal of Geriatric Cardiology, 2016, 13, 282-9.	0.2	2
1082	Platelet Function Testing-Guided Antiplatelet Therapy. Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine, 2013, 24, 90-6.	0.7	9
1083	Potential Screening for Cardiologist?. Acta Cardiologica Sinica, 2017, 33, 301-302.	0.1	0
1084	Association between CYP2C19 genotype and the additional effect of cilostazol to clopidogrel resistance in neuroendovascular therapy. Nagoya Journal of Medical Science, 2018, 80, 207-215.	0.6	5
1085	Clopidogrel resistance is common in patients undergoing vascular and coronary interventions. Vascular, 2023, 31, 58-63.	0.4	5
1086	Antiplatelet Therapy for Atherothrombotic Disease in 2022â€"From Population to Patient-Centered Approaches. Frontiers in Cardiovascular Medicine, 2022, 9, 805525.	1.1	12
1087	Prevalence and clinical impact of high platelet reactivity in patients with chronic kidney disease treated with percutaneous coronary intervention: An updated systematic review and metaâ€analysis. Catheterization and Cardiovascular Interventions, 2022, 99, 1086-1094.	0.7	1
1089	Personalizing treatments for patients based on cardiovascular phenotyping. Expert Review of Precision Medicine and Drug Development, 0, , 1-13.	0.4	0
1091	Antiplatelet therapy in cardiovascular disease: Current status and future directions. British Journal of Clinical Pharmacology, 2022, 88, 2686-2699.	1.1	21

#	Article	IF	Citations
1092	Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection After Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Cardiovascular Revascularization Medicine, 2022, 41, 115-121.	0.3	4
1093	Thromboembolic events during endovascular coiling for unruptured intracranial aneurysms: Clinical significance of platelet reactivity unit and adjunctive cilostazol. Clinical Neurology and Neurosurgery, 2022, 213, 107133.	0.6	2
1094	Biomarker Development in Cardiology: Reviewing the Past to Inform the Future. Cells, 2022, 11, 588.	1.8	2
1095	Antiplatelet Therapy Post PCI: Evaluating a Personalized Medicine Approach. Trends in Cardiovascular Medicine, 2022, , .	2.3	0
1096	Role of platelet function and genetic testing in patients undergoing percutaneous coronary intervention. Trends in Cardiovascular Medicine, 2023, 33, 133-138.	2.3	21
1097	Ischemic and Bleeding Events in PENDULUM Patients With High Bleeding Risk and High Platelet Reactivity. Circulation Journal, 2022, 86, 763-771.	0.7	9
1098	Simultaneous determination of clopidogrel, 2-oxo-clopidogrel, and the thiol metabolite of clopidogrel in human plasma by LC-MS/MS. Journal of Biomedical Research, 2022, 36, 109.	0.7	3
1099	Antithrombotic Therapy After AcuteÂCoronary Syndromes or Percutaneous Coronary Interventions inÂEast Asian Populations. JACC Asia, 2022, 2, 1-18.	0.5	15
1100	Antiplatelet Agents in Acute ST Elevation Myocardial Infarction. American Journal of Medicine, 2022, , .	0.6	0
1101	Diagnosis of Platelet Function Disorders: A Challenge for Laboratories. Hamostaseologie, 2022, 42, 036-045.	0.9	5
1102	Platelet FcÎ³RIIa Expression in Ischemic Stroke: A Marker of Increased Platelet Reactivity. , 2022, 2, .		0
1103	Genotype-Guided Use of P2Y12 Inhibitors: A Review of Current State of the Art. Frontiers in Cardiovascular Medicine, 2022, 9, 850028.	1.1	4
1104	Flow Cytometry Based Platelet Reactivity Testing to Predict the Occurrence of Per-operative Solid Microemboli During Carotid Endarterectomy. European Journal of Vascular and Endovascular Surgery, 2022, 63, 800-806.	0.8	3
1105	Antiplatelet therapy after percutaneous coronary intervention. EuroIntervention, 2022, 17, e1371-e1396.	1.4	94
1106	Platelet reactivity testing in peripheral artery disease. American Journal of Health-System Pharmacy, 2022, 79, 1312-1322.	0.5	1
1107	Association Between Platelet Reactivity and Long-Term Bleeding Complications After Percutaneous Coronary Intervention According to Diabetes Status. American Journal of Cardiology, 2022, 171, 49-54.	0.7	1
1108	Clopidogrel monotherapy in patients with and without on-treatment high platelet reactivity: a SMART-CHOICE substudy. EuroIntervention, 2021, 17, e888-e897.	1.4	7
1110	Long-term effects of baseline on-treatment platelet reactivity in patients with acute coronary syndrome and thrombocytopenia undergoing percutaneous coronary intervention. Journal of International Medical Research, 2022, 50, 030006052210817.	0.4	0

#	Article	IF	Citations
1111	Impact of the ABCDâ€GENE Score on Clopidogrel Clinical Effectiveness after PCI: A Multiâ€Site, Realâ€World Investigation. Clinical Pharmacology and Therapeutics, 2022, 112, 146-155.	2.3	7
1119	Which therapy for which condition?. , 2013, , 463-541.		1
1120	Antithrombotic agents: Platelet inhibitors, acute anticoagulants, fibrinolytics, and chronic anticoagulants. , 2013, , 332-397.		1
1121	In-vivo platelet activation and aggregation during and after acute atherothrombotic myocardial infarction in patients with and without Type-2 diabetes mellitus treated with ticagrelor. Vascular Pharmacology, 2022, , 107000.	1.0	0
1122	Evaluation of Drugs and Strategies for Treating Coronary Artery Ectasia: Update and Future Perspective. Jundishapur Journal of Chronic Disease Care, 2022, In Press, .	0.1	1
1123	Does individualized guided selection of antiplatelet therapy improve outcomes after percutaneous coronary intervention? A systematic review and meta-analysis. Annals of Medicine and Surgery, 2022, 79, .	0.5	3
1124	A Sticky Situation: Variable Agreement Between Platelet Function Tests Used to Assess Anti-platelet Therapy Response. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	5
1125	P2Y12 reaction units and ischemic and bleeding events after neuro-endovascular treatment. Journal of Stroke and Cerebrovascular Diseases, 2022, 31, 106631.	0.7	5
1126	Comparison of ticagrelor and clopidogrel in the treatment of patients with coronary heart disease carrying CYP2C19 loss of function allele. Journal of Thoracic Disease, 2022, 14, 2591-2601.	0.6	5
1127	Ideal P2Y12 Inhibitor in Acute Coronary Syndrome: A Review and Current Status. International Journal of Environmental Research and Public Health, 2022, 19, 8977.	1.2	7
1128	Antiplatelet Therapy in End-stage Renal Disease Patients on Maintenance Dialysis: a State-of-the-art Review. Cardiovascular Drugs and Therapy, 2023, 37, 975-987.	1.3	5
1129	Impact of Insulin Receptor Substrateâ€1 rs956115 and CYP2C19 rs4244285 Genotypes on Clinical Outcome of Patients Undergoing Percutaneous Coronary Intervention. Journal of the American Heart Association, 2022, 11, .	1.6	2
1130	Pharmacogenetics of Antiplatelet Therapy. Annual Review of Pharmacology and Toxicology, 2023, 63, 211-229.	4.2	9
1131	Platelet reactivity after clopidogrel loading in patients with acute ischemic stroke. Frontiers in Neurology, 0, 13, .	1.1	0
1132	Clinical Impact of Platelet Reactivity and Gene Polymorphisms in Patients With Ischemic Heart Disease After Percutaneous Coronary Intervention. , 2022, 1, 168.		0
1133	Gender-differences in antithrombotic therapy across the spectrum of ischemic heart disease: Time to tackle the Yentl syndrome?. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	7
1134	Escalation and De-Escalation of Antiplatelet Therapy after Acute Coronary Syndrome or PCI: Available Evidence and Implications for Practice. Journal of Clinical Medicine, 2022, 11, 6246.	1.0	2
1135	Modified Thromboelastography for Peri-interventional Assessment of Platelet Function in Cardiology Patients: A Narrative Review. Seminars in Thrombosis and Hemostasis, 2023, 49, 192-200.	1.5	3

#	Article	IF	Citations
1136	Effects of exercise on platelet reactivity after myocardial infarction: a randomized clinical trial. Platelets, 2023, 34, .	1.1	0
1139	Thromboelastography 6s for assessment of platelet function during coil embolization of unruptured intracranial aneurysms. Journal of Stroke and Cerebrovascular Diseases, 2023, 32, 106924.	0.7	2
1140	Stent or Scaffold Thrombosis: Past, Current, and Future Perspectives. European Medical Journal Interventional Cardiology, 0, , 55-61.	0.0	3
1141	Safety and Efficacy of CYP2C19 Genotype-Guided Escalation of P2Y12 Inhibitor Therapy After Percutaneous Coronary Intervention in Chronic Kidney Disease: a Post Hoc Analysis of the TAILOR-PCI Study. Cardiovascular Drugs and Therapy, 0, , .	1.3	0
1142	Platelet Reactivity and Clinical Outcomes After Drug-Eluting Stent Implantation. JACC: Cardiovascular Interventions, 2022, 15, 2253-2265.	1.1	8
1143	Treatment inequity in antiplatelet therapy for ischaemic heart disease in patients with advanced chronic kidney disease: releasing the evidence vacuum. Platelets, 2023, 34, .	1.1	2
1144	Antiplatelet Therapy in Coronary Artery Disease: Now and Then. Seminars in Thrombosis and Hemostasis, 0, , .	1.5	2
1145	Resistance on the Latest Oral and Intravenous P2Y12 ADP Receptor Blockers in Patients with Acute Coronary Syndromes: Fact or Myth?. Journal of Clinical Medicine, 2022, 11, 7211.	1.0	0
1146	Clopidogrel Monotherapy After 1-Month Dual Antiplatelet Therapy in Patients With Diabetes Undergoing Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2023, 16, 19-31.	1.1	4
1147	Personalized antiplatelet therapy in patients with coronary artery disease: past, present and future. Kardiologicheskii Vestnik, 2022, 17, 5.	0.1	0
1148	Genotyping genetic variants of CYP2C19 for precision antiplatelet dosing: state of the art and future perspectives. Expert Opinion on Drug Metabolism and Toxicology, 2022, 18, 817-830.	1.5	1
1149	Clinical outcomes of individualized antiplatelet therapy based on platelet function test in patients after percutaneous coronary intervention: a systematic review and meta-analysis. Journal of Cardiovascular Pharmacology, 2022, Publish Ahead of Print, .	0.8	1
1150	Role of platelet function testing in acute coronary syndromes: a meta-analysis. Open Heart, 2022, 9, e002129.	0.9	6
1151	Perspective: Collagen induced platelet activation via the GPVI receptor as a primary target of colchicine in cardiovascular disease. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	1
1152	Influence of CYP2C19 genetic variants and smoking on dual antiplatelet efficacy in patients with coronary artery disease. Frontiers in Cardiovascular Medicine, 0, 10, .	1.1	2
1153	Correlation P2Y12 Genetic Polymorphism As Risk Factor of Clopidogrel Resistance in Indonesian Stroke Patients. Vascular Health and Risk Management, 0, Volume 19, 53-61.	1.0	2
1154	Short- versus long-term Dual AntiPlatelet Therapy for Stent-Assisted treatment of CErebral aneurysm (DAPTS ACE): a multicenter, open-label, randomized clinical trial. Journal of NeuroInterventional Surgery, 2024, 16, 171-176.	2.0	2
1155	Platelet Reactivity and Cardiovascular Mortality Risk in the LURIC Study. Journal of Clinical Medicine, 2023, 12, 1913.	1.0	2

#	Article	IF	Citations
1156	Precision antiplatelet therapy. Research and Practice in Thrombosis and Haemostasis, 2023, 7, 100138.	1.0	1
1157	Antiplatelet therapy for coronary artery disease in 2023: current status and future prospects. Expert Review of Cardiovascular Therapy, 2023, 21, 311-328.	0.6	2
1161	Diabetes and Cardiovascular Disease. , 2023, , 813-835.		0